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ABSTRACT 
       Our laboratory previously found that protein-energy malnutrition (PEM) existing 
prior to brain ischemia impaired functional outcome measured in an open field test, and 
one-third of animals showed a marked increase in reactive gliosis. It was hypothesized 
that PEM worsened stroke outcome by increasing inflammation via increased activation 
of the transcription factor, nuclear factor kappa B (NFκB). Mongolian gerbils (11-12 wk 
old) were randomly assigned to a control diet (12.5% protein) or a protein-deficient diet 
(2%) for 28 days. The control group on average gained 4.9g and the PEM group lost 7.4g. 
PEM gerbils had significantly decreased food intake (P<0.001; unpaired t-test). Animals 
were then subjected to global ischemia or sham surgery, resulting in four experimental 
groups. Global ischemia was achieved by a 5 min bilateral common carotid artery 
occlusion with tympanic temperature regulated at 36.5 ± 0.2°C. PEM independently 
increased hippocampal NFκB activation by three times higher than control diet animals at 
6hr after surgery (p=0.014; 2-factor ANOVA) detected by electrophoretic mobility shift 
assay (EMSA). There was no significant effect of ischemia on NFκB activation and there 
was no interaction of diet and ischemia. Serum glucose and serum cortisol were also 
measured since both variables can be affected by PEM and can influence stroke outcome, 
but there was no significant effect of diet or ischemia. Because of the increased NFκB 
activation observed in PEM-Sham animals, a second experiment investigated if PEM also 
increased  NFκB activation in the absence of surgery. Gerbils of the same age were 
randomly assigned to either control diet or PEM for 28 days but did not receive any 
surgery. PEM consistently increased NFκB activation. Since PEM exists in 16% of 
elderly stroke patients at admission, the data suggest that PEM may worsen stroke 
 ii
outcome through increased activation of NFκB. Because increased NFκB activation was 
also observed in PEM independent of ischemia, the data also have implications for the 
inflammatory response of protein-energy malnourished elderly in general.  
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CHAPTER 1 
INTRODUCTION 
       Stroke is the fourth leading cause of death, and the leading cause of disability in 
adults in Canada (1). The pathophysiological mechanisms of stroke are still not fully 
understood. Two major mechanisms, oxidative stress and inflammation, play important 
roles in secondary damage following stroke (2, 3). The immediate reduction of blood 
supply to the ischemic brain initiates a series of cellular and molecular events. These 
events include depletion of glucose, rapid decrease of ATP production, membrane 
depolarization, glutamate excitoxicity, and calcium overload, leading to increased 
production of reactive oxygen species, other free radicals, and lipid peroxidation (2). 
Ultimately, these result in oxidative stress. Inflammation can be triggered by oxidative 
stress (4). Neutrophils infiltrate the brain immediately following stroke (5). Endothelial 
and peripheral leukocytes accumulate in the region of cerebral ischemia and are activated. 
Infiltrated inflammatory cells (leukocytes and microglia) induce toxic free radicals, 
reactive oxygen species and protease production and cause increased production of pro-
inflammatory molecule gene expression.  
       Nuclear factor kappa B (NFκB) is a key transcription factor in the inflammatory 
response, and its activation can trigger upregulation of a number of pro-inflammatory 
genes, including chemokines, adhesion molecules, cytokines, acute phase proteins, 
growth factors, and oxidant generation, promoting activity of enzymes such as 
cyclooxygenase-2 and inducible nitric oxide synthase. NFκB activation is critical for 
neurotoxic damage following stroke (6, 7). There is clear evidence that NFκB is activated 
immediately for a prolonged period in several ischemic models (8-11).  
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       Protein-energy malnutrition (PEM) exists in approximately 16% of stroke patients at 
admission to hospital (12-14). Nutritional status often worsens following the stroke. 
Rates of malnutrition can be as high as 49% at the time of transfer to rehabilitation 
services in Canada (15). PEM increases risk of morbidity and mortality following stroke. 
In a study entitled the FOOD (Feed or Ordinary Food) Trial Collaboration, 3012 stroke 
patients were investigated in 16 countries (16). The findings suggested that being 
undernourished immediately after stroke was associated with reduced survival, functional 
ability, and living circumstances six months later. A previous study in our laboratory 
showed that PEM gerbils subjected to global ischemia did not habituate as well in an 
open field test, indicating impaired functional outcome (17). Reactive gliosis 
demonstrated in one-third of PEM gerbils also suggested an increased inflammatory 
response. 
       The mechanisms by which PEM worsens stroke outcome may involve increased 
oxidative stress and inflammation in brain. Although alterations in brain glutathione 
(GSH) concentration were not found, the previous study in our laboratory suggested that 
PEM was increasing oxidative stress in ischemic hippocampus (17). In support of the 
idea that PEM is increasing the inflammatory response, increased plasma concentrations 
of several inflammatory mediators including interleukin-6 (IL-6), C-reactive protein, and 
soluble receptors of tumour necrosis factor alpha (TNF-α) have been reported in PEM 
children (18). Another study showed plasma cysteinyl leukotrienes increased in PEM (19).  
NFκB activation and production of TNF-α and interleukin-1β (IL-1β) production were 
increased in the liver of protein malnourished mice when induced with 
lipopolysaccharide; this was correlated with decreased GSH concentration (20). The GSH 
delivery agent, N-acetylcysteine, restored liver GSH and normalized NFκB activation and 
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cytokine production. The effect of PEM on the inflammatory response in brain following 
ischemia has not been explored and could be a critical factor affecting stroke outcome.  
       Therefore, the hypothesis of this thesis was that PEM worsens stroke outcome by 
increasing activation of NFκB in global ischemia. The main objective then was to 
investigate whether PEM increased activation of NFκB in gerbil hippocampus following 
global ischemia.  Since PEM may affect serum glucose (21-23) and serum glucocorticoid 
(GC) concentrations (24) and both factors have been demonstrated to influence ischemic 
brain injury (25, 26), a second objective was to investigate if these factors were 
influenced by PEM or ischemia in the models used for this study.  GCs were of additional 
interest because they can directly regulate NFκB activation (27).  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Stroke as a Health Issue 
         Stroke is the fourth leading cause of death in Canada and it costs the Canadian 
economy $2.7 billion a year (1). Each year, between 40,000 and 50,000 reported strokes 
occur in Canada. About 16,000 Canadians die from stroke and it also causes a high rate 
of disabilities. In the UK and the USA, approximately 100,000 and 500,000 reported 
strokes occur every year, respectively (28). Stroke in the developing world is less well 
documented (29). A consensus statement from the Asia-Pacific Consensus Forum on 
Stroke Management predicts that in the next 30 years the burden of stroke will grow most 
in developing countries rather than in the developed world (29). In China, for example, 
stroke is becoming the leading cause of death, and about 2 million new reported strokes 
occur each year (30). 
      The rate of stroke survivors returning home has increased since 1970 (28, 31). The 
stroke mortality rate has declined in the USA, and similar declines have also occurred in 
most other western countries because of improved public medical care, hygiene, and 
nutrition (31). Despite this decreased rate of mortality, there are still no therapeutic 
effective treatments for stroke. Dietary intervention is one modifiable factor that could 
not only influence the prevalence of stroke but also its course and outcome (28). 
Finestone and coworkers (15) found that 49% of stroke patients had PEM at the time of 
admission to rehabilitation units, suggesting that immediate post-injury poor nutritional 
status could damage the antioxidant defense system (15, 32). The FOOD Trial 
Collaboration also demonstrated that stroke patients who are undernourished immediately 
after stoke had reduced survival, functional ability, and living circumstances six months 
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later (16). Therefore, this thesis focuses on the impact of PEM on ischemic brain injury, 
and specifically on the inflammatory response by evaluating a key transcription factor, 
NFκB. 
 
2.2 Mechanisms of Ischemic Brain Damage 
2.2.1 Membrane depolarization, glutamate excitotoxicity, and intracellular calcium   
         overload 
      During ischemia, the cerebral blood flow (CBF) reduction is greatest in the center of 
the ischemic area, also called the core. The peripheral region of the ischemic territory, 
called the penumbra, is the region in which the ischemic damage is potentially reversible 
(31, 33). Brain tissue has a relatively high consumption of oxygen and glucose and 
depends mostly on oxidative phosphorylation for energy production (4). Restriction of 
the delivery of oxygen and glucose during brain ischemia impairs the energy requirement 
of maintaining ionic gradients. When blood flow reaches 50% of its normal rate, 
oxidative energy production falls severely and anaerobic energy production leads quickly 
to lactate production (34). Energy failure is probably the predominant mechanism of cell 
death in the ischemic core because failure of the sodium-potassium ATPase and other 
energy-dependent ionic pumps leads the neuron to lose its ionic gradients (33, 35, 36). 
With energy depletion, membrane potential is lost and neurons and glia depolarize.  
      Once the membrane is depolarized, voltage-dependent Ca2+ channels become 
activated (37, 38). Ca2+ moves into the cell and excitatory amino acids are released to the 
extracellular space (2, 39).The extracellular Ca2+ concentration is relatively high 
compared to the cytoplasm Ca2+ concentration (40). The influx of Ca2+ to the cell initiates 
a wide variety of harmful events that cause neuron death. It overactivates numerous 
 5
enzyme systems, such as proteases, lipases, and endonucleases to produce toxic free 
radicals (3, 38). Free radicals can induce the formation of inflammatory mediators which 
activate microglia and lead to the invasion of blood-borne inflammatory cells (leukocyte 
infiltration) via upregulation of endothelial adhesion molecules (41, 42). When free 
radicals are generated, they can damage the membrane, mitochondria and DNA, in turn 
triggering apoptosis.  
      When the membrane is depolarized, another damaging event is that the glutamate-
sodium transporter cannot work efficiently, and glutamate accumulates extracellularly (2, 
4, 33, 37). Activation of specific ionotropic and metabotropic glutamate receptors 
dramatically increases intracellular Ca2+, Na+, and Cl- levels, while K+ released into the 
extracellular space can propagate a series of spreading waves of depolarization (3, 4, 33). 
Water shifts to the intracellular space via osmotic gradients and causes edema. 
 
2.2.2 Oxidative damage 
      Oxidative stress has been suggested to be involved in the pathogenesis of cerebral 
ischemia and reperfusion injury (2, 43, 44). The brain is particularly vulnerable to 
oxidative stress due to its relatively high consumption of oxygen, high concentration of 
iron and lipids with unsaturated fatty acids, and its relatively low concentration of 
antioxidants compared to the liver or kidney (45). At reperfusion after ischemic insult, 
several molecular events such as phospholipase activation, lipid peroxidation and 
dysfunction of the mitochondrial respiratory chain all have been shown to lead to the 
production of free radicals (44).  
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2.2.2.1 Oxidant generation system 
      A main event during cerebral ischemia is the generation of free radicals and other 
oxidant species; due to their high reactivity, they provoke damage to lipids, DNA, and 
proteins, leading to neuronal death (44). They also contribute to the breakdown of the 
blood brain barrier (BBB). These reactive species include reactive oxygen species (ROS), 
such as superoxide anion, hydrogen peroxide, hydroxyl radical, hypochlorite and singlet 
oxygen, and reactive nitrogen species (RNS), such as nitric oxide radical (NO•) and 
peroxynitrite (ONOO- ) (2, 33, 37). 
      Superoxide anion can be produced at several sites in the cell. The most important 
source of superoxide anion in normal healthy aerobic cells is the mitochondrial electron-
transport chain (2). The mitochondrial respiratory chain consists of a series of electron 
carriers and is organized into four complexes. Some of the electrons (approximately 2 to 
5%) passing through these carriers consume O2 to produce superoxide instead of being 
fully reduced to water (2). 
      During ischemia, the above-mentioned Ca 2+ influx activates phospholipase A2 (37, 
38). This enzyme liberates the unsaturated fatty acid arachidonic acid and then initiates 
the formation of free radicals via the cyclooxygenase and lipoxygenase pathways in the 
presence of NADH or NADPH (2, 37). Other prooxidant enzymes that generate 
superoxide anion are NADPH oxidase and xanthine oxidase (2). 
       Among ROS, superoxide is directly toxic to neurons (46). In addition, evidence 
suggests that superoxide contributes indirectly to tissue damage by enhancing vasogenic 
edema and BBB disruption after brain ischemia (47). The role of superoxide in 
exacerbating BBB is supported by the evidence that endothelial cells are the cellular 
constituents of BBB, and also the major source of superoxide production (47). 
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      Although superoxide anion itself is a weak oxidant, it can react with a variety of 
molecules to produce stronger oxidants. It reacts with thiols, thus causing the release of 
arachidonic acid, which initiates an arachidonate metabolic cascade resulting in more 
superoxide anion production (2).  Superoxide anion can also react with NO• to produce 
the strong oxidant, ONOO-(2). Superoxide anion is converted by the enzyme superoxide 
dismutase (SOD) to hydrogen peroxide (2). 
      Superoxide anion can reduce Fe3+ to Fe2+.  Fe3+ is  normally bound to ferritin, a 
multimeric iron-carrying protein. Under the hypoxia-ischemia condition, in which the 
environment is acidic, superoxide anion is converted to the peroxyl radical and converts 
ferritin bound Fe3+ to free iron Fe2+. Free Fe2+ reacts with hydrogen peroxide and 
generates strong oxidants, the hydroxyl radicals. These are also called the Haber-Weiss 
reaction. Hydroxyl radical is particularly reactive in the cell. Once formed, it can abstract 
an electron from most macromolecules, including thiol-containing enzymes, such as GSH 
reductase and GSH peroxidase, two important enzymes in antioxidant defense system. It 
also reacts with DNA, causing DNA strands to break or causing increased potential for 
mutagenesis through the hydroxylation of DNA bases. In addition, it can attack the 
methylene carbon of the polyunsaturated fatty acids leading to a lipid peroxidation chain 
reaction (reviewed in (2)).  
      Singlet oxygen can be formed by several reactions, including two superoxide anions 
interacting spontaneously, hypochlorite interacting with hydrogen peroxide, ONOO-
interacting with hydrogen peroxide and the Haber-Weiss reaction (48). Singlet oxygen 
can oxidize polyunsaturated fatty acids and generate lipid hydroperoxide, a powerful 
oxidant that is able to initiate the propagation of lipid peroxidation chains with transition 
ions, inactivate SOD and catalase, and also produce DNA-damaging singlet oxygen (2).  
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      NO• is a physiological messenger in the central nervous system (CNS) that is formed 
from L-arginine and O2 in a reaction catalyzed by nitric oxide synthase. Although NO• 
seems to be implicated in important functions in the CNS such as regulation of cerebral 
blood flow or memory (48-50), it can also have damaging effects. Both leukocytes and 
glial cells can synthesize NO• via different mechanisms involoving inducible nitric oxide 
synthase (iNOS) (37, 48), whereas endothelial cells can produce NO•  by activation of 
endothelial nitric oxide synthase (eNOS) (37). NO• can interact with superoxide anion to 
produce ONOO-, which can oxidize thio-containing proteins, DNA bases and 
polyunsaturated lipids. ONOO- can also inhibit mitochondrial electron transport, leading 
to decreased ATP production and increased production of ROS (37, 48).  
      NO• levels have been found to be elevated in rat middle cerebral artery occlusion 
(MCAO), an experimental model of stroke. Several sources for NO• overproduction 
caused by cerebral ischemia have been reviewed (51-53). The noted elevation in 
intracellular Ca2+ after ischemic insult is a likely trigger of NO• production via neuronal 
nitric oxide synthase (nNOS) activation.  
      Lipid peroxidation is initiated when a hydrogen atom is abstracted from a methylene 
carbon in a polyunsaturated lipid, resulting in a lipid radical (2). This lipid radical can 
interact with O2 molecules to generate a peroxyl radical. The peroxyl radical can be 
converted to a lipid hydroperoxide resulting in the formation of a new lipid radical (54). 
This chain of peroxidation has the ability of self-perpetuation. Lipid peroxidation is one 
of the most damaging events since it greatly alters the fluidity of the membrane and 
affects a variety of membrane functions including increasing the permeability of the 
membrane to ions and decreasing various membrane ATPase activities (4, 55). It is also 
dangerous because hydroperoxides can interact with transition element ions and give rise 
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to lipid alkoxyl and lipid peroxyl radicals (2, 54). In turn, this can initiate new rounds of 
lipid peroxidation chains.   
 
2.2.2.2 Antioxidant defense systems 
      Antioxidants together act as a defense system by inhibiting free radical production, 
scavenging free radicals, and increasing their degradation (56). Antioxidant defense 
systems include two categories, non-enzymatic and enzymatic antioxidants. Some of the 
major non-enzymatic antioxidants include tocopherol (Vitamin E), ascorbic acid, uric 
acid and reduced-GSH. Enzymatic antioxidants include the thioredoxin system, SOD, 
catalase and the family of glutathione peroxidases (GPx) (56). Thioredoxins (Trx) are a 
class of small 12-kDa redox proteins known to be present in all eukaryotic and 
prokaryotic organisms. They are characterized by a highly conserved active site that 
contains two cysteine residues which are reduced from the oxidized form by the 
flavoenzyme Trx reductase and NADPH. Therefore, Trx can scavenge free radicals and is 
able to protect cells against oxidative stress. 
       Both catalase and GPx can scavenge peroxides and convert them to water and 
molecular oxygen (48, 56). However, catalase is mainly located in a cell organelle called 
the peroxisome, while GPx widely exists in the cells. Moreover, the GPx can scavenge 
both hydrogen peroxides and organic peroxides. GPx requires GSH as an electron donor 
(56).  
      In the antioxidant defense system, GSH plays a central role. It not only enables GPx 
to scavenge all peroxides, but is also important in the regeneration of tocopherol from the 
tocopheroxyl radical (56). The importance of GSH in the antioxidant defense system can 
also be supported by the fact that supplementation of a GSH delivery agent dramatically 
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decreases free radicals following ischemia. N-acetylcysteine has been reported to 
effectively decrease ROS, such as hydroxyl radicals, hydrogen peroxide, and peroxyl 
radicals, and also to increase the endogenous GSH synthesis following ischemia (57).  
 
 2.2.2.3 Oxidative stress after ischemia 
      To measure free radical levels in the brain is rather difficult due to their low 
concentration and short half-life. In most studies, indirect techniques, such as irreversible 
damage in biological macromolecules or increased consumption of endogenous 
antioxidants, are used to evaluate oxidative stress (45). Early oxidative stress has been 
shown as soon as 30-60 min after ischemia. This oxidative stress is characterized by a 
drop in concentrations of GSH, Vitamin C (58), Vitamin E, and ubiquinol-10 , associated 
with an increase in malondialdehyde (MDA) and lipid-conjugated diene levels (54). 
Other studies have found production of hydroxyl radicals and superoxide anions 
immediately after ischemia as well as from several hours up to 21 days after ischemia 
(59-61). Candelario-Jalil et al (62) have demonstrated the time course of oxidative 
damage in different brain regions following ischemia in gerbils. Sustained lipid 
peroxidation and decreased antioxidant enzyme activity were shown in the gerbil 
hippocampus up to 7 days following ischemia.  
      Several studies have demonstrated increased levels of lipid peroxidation markers in 
the plasma, erythrocytes, and blood of stroke patients, by using an assay to measure total 
thiobarbituric acid-reactive substances (TBARS) (63), or MDA (64). 
 
2.2.3 Inflammation 
      Inflammation is a series of responses of vascularized tissues of the body to injury (41). 
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The primary objective of inflammation is to localize and eliminate the irritant and repair 
the surrounding tissue. For the survival of the host, inflammation is a necessary and 
beneficial process (41). The acute inflammatory response involves three major stages: 
first, dilation of capillaries to increase the blood flow; second, microvascular structural 
changes and escape of plasma proteins from the blood stream; and third, leukocyte 
transmigration through the endothelium and accumulation at the site of injury (41, 42). 
Brain inflammation during ischemia-reperfusion is believed to play an important role in 
the development of secondary damage through its ability to increase the accumulation of 
inflammatory cells and microvascular dysfunction (5, 41). 
      Inflammation is mediated by a complex array of mechanisms involving both cellular 
and molecular components (5). A large amount of evidence has been accumulated that 
numerous brain cells have an immediate or prolonged inflammatory response following 
ischemia.  
 
2.2.3.1 Peripheral leukocytes 
      Leukocyte infiltration into brain infarction is a widely documented histopathological 
event in experimental models of stroke, but also is routinely observed in patients 
suffering from stroke. Leukocytes are considered to be key mediators of the host response 
in reperfusion injury in the brain (65). They are the main cellular components of the 
immune system. Granulocytes, which can be further divided into three lineages of cells, 
neurophils, eosinophils and basophils, are the first hematogenous cells that appear in the 
brain in response to ischemia. In a MCAO model, granulocytes have been shown to 
accumulate in cerebral vessels as early as 30 minutes after the onset of insult, prior to the 
infiltration to the infarction core and penumbra (65-67). The highest number of 
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intravascular neutrophils was found at 12 hr after occlusion, whereas the number of 
granulocytes peaked in ischemic parenchyma 24 hr after occlusion (66). 
      Evidence suggests that leukocytes may play a key role leading to secondary brain 
damage after ischemia. First of all, a correlation has been reported between poly-morphic 
neutrophil (PMN) accumulation in the ischemic zone and the expansion of cerebral 
damage in human brain (68). Secondly, neutropenia (decreased circulating neutrophils) 
has a beneficial effect on reperfusion injury after ischemia (69, 70). Thirdly, genetic 
manipulations or treatments that prevent PMN recruitment and adhesion to microvessel 
endothelia are protective against cerebral ischemia (71, 72). Moreover leukocytes 
produce proteolytic enzymes, ROS, and other inflammatory mediators that may 
contribute to additional damage (43). For example, iNOS has been shown to be active 
and to produce toxic NO· in infiltrating neutrophils (51, 52). Other free radical producing 
mechanisms in neutrophils include NADPH oxidase (73).  
 
2.2.3.2 Microglia 
      Microglia are the resident macrophage cell population and represent the primary 
immunocompetent cells within the CNS. Microglia comprise 10-20% of the total glial 
cell population in the CNS and act in concert with astrocytes and neurons to maintain 
normal brain homeostasis (74). They respond to several neurotransmitters and have a 
capacity to release regulatory molecules involved in inflammation, such as cytokines (75). 
Moreover, together with astrocytes, they release trophic factors such as nerve growth 
factor and basic fibroblast growth factor. 
      Microglia are involved in several pathological situations. They react to invasion by 
infectious agents and participate in removing cellular debris after traumatic or ischemic 
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injury. Upon stimulation, microglia transform into the ameboid shape characteristic of 
activated microglia (76). In focal cerebral ischemia, microglial activation occurs very 
rapidly within hours after the onset of ischemia and persists for weeks (77, 78). For 
example, in MCAO models, increased immunoreactivity for phosphotyrosine or isolectin 
(markers for microglia) can be detected as early as 3-6 hr after the onset of ischemia (79, 
80). Moreover, activated microglia with ameboid shapes and retracted processes are 
clearly seen 24 hr after the ischemia. 
      Several inflammatory mediators are produced by microglia in ischemic insults. 
Classical inflammatory mediators produced by microglia are cytokines such as IL-lα, IL-
lβ, IL-6 and TNF-α (75). Moreover, lipid derivatives such as arachidonic acid and 
prostaglandins, as well as free radicals such as superoxide and NO•, are produced. Free 
radicals or ROS produced by brain microglia promote abnormal phagocytic activity of 
microglia leading to further damage of ischemic tissue (81). Enzymes catalyzing the 
production of several pro-inflammatory mediators are also produced in microglia. These 
include, for example, cyclooxygenase 2 (COX-2), matrix metalloproteinase (MMPs), 
caspase-l, and iNOS (82-85).  
      Microglia have also been shown to produce beneficial and anti-inflammatory 
mediators that may protect from the ischemic insult. These mediators include trophic 
factors like transforming growth factor-β and cytokines such as interleukin10 (IL-I0) and 
the antiapoptosis protein Bcl-2 (86-88).  Moreover, phagocytosis of cellular debris from 
degenerated neurons has been shown to support wound healing and peripheral neuronal 
regrowth (89), and the secretion of beneficial molecules can support neuronal recovery 
(90).  
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2.2.3.3 Vascular endothelium and the blood-brain barrier 
      Loss of vascular integrity is a widely described phenomenon in cerebral ischemia. 
There are anatomical and functional barriers that maintain vascular integrity as well as 
the transport and transmigration of circulating blood cells. The BBB is a membrane that 
controls the passage of substances from the blood into the central nervous system. It 
enables fluid retention within plasma space and prevents cellular extravasation during 
normal conditions. Several factors and mechanisms affect the integrity of the BBB. 
Ischemia, inflammation and inflammatory mediators (cytokines, adhesion molecules), 
free radicals, and proteases (MPPs, plasminogen activators, thrombin) have been 
suggested to increase BBB permeability and subsequent vascular edema in several 
experimental stroke settings (91). For example, a 3 -hr transient MCAO occlusion 
followed by a 3 -hr reperfusion period in rats has been shown to cause a significant 
increase in permeability of the BBB (92). A dysfunctional BBB and brain edema appear 
to play an important role in the development of brain damage in animal models of brain 
ischemia. Moreover, clinical manifestations of ischemic brain edema as a result of 
impaired BBB function is one of the most important causes of clinical deterioration and 
death within the first 2-5 days after stroke (93). 
 
2.2.3.4 Neurons 
      There are reports showing that neurons themselves can produce inflammatory 
mediators and enzymes that may contribute to tissue injury progression. For example, 
Nagayama et al (94) showed that COX-2 is produced in neurons after ischemia. In 
addition to COX-2, neurons are able to produce cytokines such as IL-6, IL-1 and TNF-α 
in response to injury (95-97). 
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Summary 
       There is abundant evidence that inflammation contributes to the development of 
secondary brain damage following stroke. The increased free radical generation in 
ischemia induces the expression of a wide variety of pro-inflammatory molecules, 
including a number of cytokines and chemokines, by triggering the activation of 
transcription factors, including NFκB, interferon regulatory factor 1, and hypoxia 
inducible factor 1 (3). Cytokines such as TNF-α, IL-1β and chemokines can upregulate 
the expression of adhesion molecules on endothelial cells, leukocytes and platelets, 
leading to infiltration of leukocytes into the brain parenchyma (5). Cell adhesion 
molecules, including intercellular adhesion molecule 1 (ICAM-1), P-selectins and E-
selectins, interact with complementary surface receptors on neutrophils, leading to 
neutrophil infiltration. Cytokines can also activate microglia, while chemokines directly 
guide the migration of bloodborne cells towards their targets. Inflammatory cells 
(leukocytes and microglia) contribute to brain damage by producing free radicals and 
other toxic inflammatory molecules that lead to blood brain barrier dysfunction, edema, 
and cell death (5).  
      The mechanisms of inflammation causing brain damage are characterized by the 
accumulation of inflammatory cells and inflammatory mediators in the ischemic brain. 
These inflammatory mediators also include enzymes that promote the production of 
reactive oxygen and nitrogen species, which can damage tissues by disrupting cell 
membranes, altering DNA and ultimately leading to apoptosis. Two important regulatory 
enzymes being generated in this process are iNOS and COX-2. iNOS is an enzyme that 
converts L-arginine to toxic amounts of NO. It is not normally found in most cells. 
Associated with inflammation in ischemia, iNOS is induced in neutrophils infiltrating the 
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brain, cerebral blood vessels (53, 98) and in activated microglia (99). Ischemic neurons 
also express COX-2, an enzyme that mediates ischemic injury by producing superoxide 
and toxic prostanoids (3).  
 
2.2.4 The transcription factor, NFκB 
      Under ischemic conditions, the increased oxidative stress and production of pro-
inflammatory substances can trigger activation of a key transcription factor, NFκB. NFκB 
is a ubiquitous transcription factor composed of a complex of proteins which are critical 
regulators of a variety of responses, especially in inflammation. Indeed, NFκB was 
originally identified from the B-cells of the immune system, being a nuclear factor that 
bound to the site in the immunoglobulin κ enhancer (100). Since then, NFκB has been 
shown to have a central role in the inflammatory response and in several diseases.  
 
2.2.4.1 Molecular properties of NFκB  
      NFκB is a DNA binding protein which has five known NFκB/Rel/Dorsal (NRD) 
family proteins, p65 (also called RelA), p50, cRel, RelB and p52 (101, 102). The active 
forms of NFκB are dimers most frequently composed of the two DNA binding subunits, 
p50 and p65. NFκB is widely expressed in numerous tissues including the CNS (102).  
      NFκB, when activated, can quickly upregulate gene expression without the delay 
required for protein synthesis. This ability for a quick response to stimulation is because 
it preexists in the cytoplasm of most cells in an inactive form non-covalently bound to the 
inhibitor IκB (101, 102). There are six known members of the IκB family, including the 
two most studied ones, IκBα and IκBβ. The N-terminal region of IκB proteins contains 
both phosphorylation and ubiquitination sites, both vital for NFκB activation and 
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subsequent IκB protein degradation by proteosome (103). IκBα is a 37-kDa protein and it 
regulates NFκB activity by a rapid process (102). IκBα contains a κB promoter which can 
be transcriptionally upregulated by NFκB. This dramatically decreases the time required 
for IκB to re-inhibit NFκB. The persistent activation of NFκB is regulated by IκBβ, a 
continuing inducing agent which causes NFκB to be maintained in the nucleus.  
 
2.2.4.2 Activation of NFκB 
      A wide variety of stimuli can activate NFκB, including cytokines such as TNF-α, IL-
1β, bacteria such as lipopolysaccharide (LPS), growth factor, stress, and UV light. Many 
ischemia-induced factors, such as inflammatory cytokines, increased intracellular Ca2+, 
and glutamate excitotoxicity, also can cause NFκB activation (104, 105). These stimuli 
activate the phosphorylation of IκB kinase (IKK), the key step in IκB protein 
phosphorylation. Indeed, the extent to which IKKs are activated seems to dictate the 
extent of IκB degradation and subsequent NFκB activation (106, 107). Three different 
IKK-kinases have been described; IKKα and IKKβ are functional kinases (108), whereas, 
the third IKKγ, is suggested to link the IKK- complex to upstream activators. Following 
phosphorylation, IκB is targeted for destruction by the ubiquination-proteosomal 
degradation pathway, allowing the translocation of NFκB to the nucleus. Once 
translocated, NFκB dimers bind to a specific DNA motif and regulate transcription of 
target genes containing NFκB consensus sequences in their promoter region (109). Figure 
2.1 shows the NFκB activation signaling pathway as well as some of the target genes. 
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Figure 2.1 NFκB activation signaling pathway. Inactivated p50/p65 NFκB dimer binds to 
its inhibitor IκB in cytoplasm. Stimuli such as LPS, TNF-α and IL-1β can activate the 
enzyme, IKK, and promote ROS production. IKK, which can also be activated by ROS, 
activates IκB phorsphorylation which leads to IκB degradation. This allows p65 and p50 
to translocate to the nucleus and bind to the target gene. This causes increased mRNA 
expression of a number of pro-inflammatory molecules, including iNOS, TNF-α, IL-1β, 
ICAM-1, and cycloxygenase-2 (COX-2).  
 
2.2.4.3 Inflammatory gene expression regulated by NFκB 
NFκB is a key regulator of inflammation because its activation can trigger upregulation 
of a number of pro-inflammatory genes, including cytokines, chemokines, adhesion 
molecules, acute phase proteins, growth factors, immunoreceptors, and enzymes such as 
COX-2 and iNOS (Table 2.1). These pro-inflammatory genes all share the common 
NFκB binding sequences in their promoters. 
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Table 2.1 Major NFκB responsive inflammatory genes  
Gene Reference 
TNF-α (110) 
Interleukins (IL-1, -2, -6, -8, -10, -12) (111-116) (117-119) 
COX-2 (120, 121) 
iNOS (122) 
ICAM-1 (123) 
VCAM-1* (124) 
E-selectin (125) 
MnSOD* (126) 
* VCAM-1: vascular cell adhesion molecule 1; MnSOD: manganese superoxide dismutase. 
 
2.2.4.4 NFκB activation in stroke models 
       Activation of NFκB appears to be critical for neurotoxic damage following stroke, 
and there is clear evidence that NFκB is rapidly activated in several ischemia models.  
Salminen et al (9) demonstrated a time-dependent change in transcription factor binding 
activities, including NFκB, in a transient focal cerebral ischemia model. Focal and global 
ischemia are two types of experimental models of stroke, based on the reduction of blood 
flow in a defined brain area and blood flow to the whole brain stopped, respectively. 
Subsequently, immunohistochemistry in the human brain was used to demonstrate that 
there is an enhancement of NFκB staining in glial cells in the infarct areas (127). Based 
on recent reports, the most prominent NFκB activation after brain ischemia is seen in 
neurons in both focal and global ischemia (10, 11, 128, 129). Two key investigations in 
1997 by Clemens et al (10, 11) illustrated details of the time course and the cell types in 
which NFκB is upregulated. Using a transient forebrain global ischemia model, increases 
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of NFκB p50 and p65 immunoreactivity were mainly located in neurons in the 
hippocampal CA1 region (10). The p50 subunit of NFκB showed an increase as early as 6 
hr following global ischemia with an increasing intensity over 12 and 48 hr followed by a 
decreased intensity at 96 hr (11). However, one limitation of this study is that the results 
are reliant solely on western blot, which has lower specificity compared with the 
electrophoresis mobility shift assay (EMSA) in analyzing NFκB activation. Although 
these studies of cerebral ischemia had relatively short time frames, there is some evidence 
that the increase in NFκB may be quite prolonged in some cells. Domanska-Janik et al (8) 
have also shown NFκB activation in the dorsal part of the hippocampus as early as 3 hr 
after global ischemia and for up to 7 days following the insult. Importantly, Schneider et 
al (130) showed that genetic disruption of inducible NFκB activity in p50 knock-out mice 
was able to prevent neuronal cell death significantly in a focal transient ischemia model, 
supporting a direct cell death promoting role for NFκB in ischemia. However, causality 
between NFκB activity and neuronal cell death has not been established well enough in 
brain disease models. Transient NFκB activation in ischemic injury may also have some 
benefit, whereas more prolonged activation may be detrimental. NFκB DNA-binding 
activity decreased in hippocampus of mice lacking p50 has also been reported to enhance 
neurodegeneration in both hippocampus and striatum following focal ischemia (131). 
Whether NFκB activation is neurotoxic or neuroprotective still needs to be further 
investigated. 
 
2.2.4.5 Redox regulation of NFκB activation 
      Cell redox status has been demonstrated to have a clear role in regulating NFκB 
activation. This is supported by three types of evidence. First, as reviewed by Christman 
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(132), most of the stimuli of NFκB activation that can activate IKK, such as 
lipopolysaccharide, TNFα, IL-1β and hydrogen peroxide, produce oxidative stress in the 
cell. Secondly, treatment with oxidants increases NFκB activation; hydrogen peroxide 
has been shown to directly activate NFκB activation (133). Overexpression of SOD, 
which causes increasing production of hydrogen peroxide, enhances the TNFα-induced 
activation of NFκB (128). Third, the cysteine prodrug, N-acetylcysteine, has been 
demonstrated to inhibit NFκB activation and protect against ischemia (134). Shen et al 
(135) also demonstrated that N-acetylcysteine and pyrrolidine dithiocarbamate reduce 
neuronal loss in rat hippocampus after global ischemia through inhibition of NFκB 
activity. 
 
2.3 Protein-Energy Malnutrition  
 
2.3.1 PEM as a clinical problem and its determinant role in stroke outcome 
       The elderly are both a group at high risk for stroke (136) and they are vulnerable to 
poor nutritional status due to factors such as eating disorders, poor dental status, drug side 
effects, decreased physical activity and metabolism, and chronic diseases (137-139). 
There are two lines of protein-energy deficiency, called kwashiorkor and marasmus. In 
kwashiorkor, the diet is low in protein but provides enough Calories. Serum albumin is 
decreased, skin and hair show dyspigmentation, and edema and fatty liver also occur 
(139). In marasmus, there is general insufficient energy intake with protein deficiency. 
Patients suffer with muscle wasting and loss of subcutaneous fat, but do not present with 
edema, hypoalbuminemia, or fatty liver (139). In North America, the most commonly 
seen protein deficiency in hospitalized patients is PEM, which is a combination of both 
conditions (140).  
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       Compromised protein-energy deficiency has been reported for stroke at the time of 
admission to hospital (13, 14, 16, 93, 141, 142) and during the hospital stay (13, 14, 16, 
93, 141, 142) using anthropometric, haematological and biochemical characters for 
assessment of nutritional status. In a study in an Australian private hospital, 19.2% of 
stroke patients were malnourished on admission and this was associated with a 
significantly greater patient-generated subjective global assessment score (a global 
assessment for malnutrition) and lower body weight (143). Forty-nine% of Canadian 
stroke patients at the time of admission to rehabilitation units had PEM, with dysphagia 
reported in 47% (15, 32). They suggested there was inadequate nutritional intervention 
immediately post-injury which could compromise antioxidant defense mechanisms (15, 
32). Nyswonger et al (144) demonstrated that the length of time to start of feeding after 
stroke varies, and stroke patients fed within seventy-two hours of injury have a shorter 
hospital stay. Among the various markers of nutritional status, low serum albumin 
concentration is the only one that showed a significant and independent association with 
various outcomes such as longer lengths of hospital stay and higher mortality rates in 
stroke patients (12-14, 32, 136, 141, 142, 145). Albumin synthesis initially decreases in 
PEM. With severe protein deficiency, the synthesis of albumin and other serum protein 
decreases dramatically, resulting in decreases in osmotic pressure and extravasation of 
water and edema (146). However, serum albumin  has limitations as an indicator of 
protein status because it is also influenced by many other conditions as well as by liver 
and renal disease (14, 142, 147).  
       In a recent study entitled the FOOD Trial Collaboration, 3012 stroke patients were 
investigated in 16 countries (16). It was found that being undernourished immediately 
after stroke was associated with reduced survival, functional ability, and living 
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circumstances six months later. This study suggests that PEM influences stroke outcome, 
but a major limitation of this study was the absence of standardization of assessments of 
nutritional status. A recent study done by our laboratory in a global ischemia model in 
gerbils (17) suggested that the association shown by the FOOD Trial is causal. Ischemic 
animals subjected to PEM did not habituate as well in an open field test, which is a 
functional measure of brain injury. A subgroup also displayed thigmotaxis (a preference 
for the outer perimeter of the open field) and marked reactive gliosis. The reactive gliosis 
suggested that PEM might be influencing the inflammatory response in stroke and may 
be a critical determinant of stroke outcome.  
 
2.3.2 PEM and ischemic brain damage: mechanisms 
2.3.2.1 PEM and redox status, inflammation and NFκB activation 
       Although impaired immune function (T-cell subsets, lymphocyte proliferation and 
cytokine production) has been observed in elderly patients with PEM (148, 149), an 
abnormal or prolonged inflammatory response can also occur in PEM.  In one study in 
PEM children, plasma concentrations of several inflammatory mediators, including IL-6, 
C-reactive protein, and soluble receptors of TNF-α, were found to be greater (18). 
Increased endogenous cysteinyl leukotrienes leading to increased edema has also been 
reported in kwashiorkor patients (19). The age of onset of PEM may influence effects on 
the inflammatory response since the production of a number of cytokines has been 
reported to be decreased by PEM in adolescent animals but increased in middle-aged 
animals (150).  
       Previous work in our laboratory suggests that PEM may increase the inflammatory 
response in brain ischemia. In this study, it was reported that one-third of PEM gerbils 
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exposed to global ischemia showed dramatic increases in reactive gliosis in the 
hippocampus at 10 days after the insult (17). Although the glial cell type was not 
identified, it is known that both microglia (151) and astrocytes (152) are activated after 
global ischemia. The reactive gliosis suggested an increased inflammatory response 
because reactive astrocytes can produce and release inflammatory mediators such as 
cytokines and chemokines (153), and microglia can produce toxic molecules including 
pro-inflammatory cytokines and also reactive species including NO, oxygen radicals and 
arachidonic acid derivatives (154). 
       An important question is how PEM could enhance the inflammatory response in the 
post-ischemic period. Li et al (20) have reported that protein malnutrition causes 
increased  NFκB activation in liver in response to lipopolysaccharide as well as 
increasing mRNA for its target genes, TNFα and IL-1β. This has never been studied in 
brain, but given the key role of NFκB in promoting inflammation following brain 
ischemia (8, 10, 11, 155), this is a potential mechanism by which PEM enhances 
inflammation and worsens functional outcome. Effects of PEM on NFκB could be 
mediated by  an alteration in GSH concentration and redox state. In liver, 
supplementation of the GSH delivery agent, N-acetylcysteine, normalized 
lipopolysaccharide-induced NFκB activation, restored liver GSH level, and decreased 
TNFα and IL-1β mRNA (20). 
       GSH is an important antioxidant for scavenging peroxides (2). As well as playing a 
central role in the antioxidant defense system, it is important in redox regulation of NFκB 
activation (20, 133). Cellular GSH concentration is determined by several factors 
including consumption by formation of conjugates via GSH S-transferase, extent of 
oxidation, de novo synthesis, and reduction of oxidized GSH by GSH reductase (55). 
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Activity of the γ-glutamylcysteine synthetase and availability of cysteine are the rate 
limiting factors for GSH synthesis (55). The most important source of cysteine is the diet. 
If dietary cysteine is decreased, GSH may be used to supply cysteine for critical proteins, 
limiting the amount of GSH available for antioxidant defense. Liver GSH responds to the 
protein, cysteine, and energy content of the diet (156). When mice are fed a low-protein 
diet, hepatic GSH is depleted and after supplementation with a cysteine precursor, hepatic 
GSH can be increased beyond the physiological maximum (157). GSH concentration is 
also reduced in lungs of protein-energy malnourished rats but can be increased with the 
cysteine prodrug, L-2-oxothiazolidine-4-carboxylate (OTC) (158).  
       PEM may increase NFκB activation by decreasing brain GSH and enhancing 
ischemia-induced oxidative stress. However, brain GSH concentration appears to be more 
tightly regulated by mechanisms in the brain and less responsive than other tissues to diet 
although acute, severe sulfur amino acid deficiency decreases GSH in a number of brain 
regions (159). It was hypothesized in a previous study from our laboratory that PEM 
would exacerbate a global ischemia-induced depletion of GSH due to decreased substrate 
for synthesis in the face of increased demand (17). Although this was not found in 
hippocampus or neocortex, the limitation of that study is that only one timepoint (12 hr) 
was assessed post-ischemia, and there was considerable variability in ischemic damage. It 
is also possible that PEM increases NFκB activation through an increase in oxidative 
stress that is independent of a change in GSH concentration. This is supported by the 
study of Bobyn et al. (17) which showed independent PEM- and ischemia-induced 
decreases in hippocampal protein thiols and a trend for GSH reductase to decrease with 
ischemia only when the animals were also PEM. These serve as markers of oxidative 
stress because of the susceptibility of thiol groups to oxidation (160). Thus, PEM may 
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affect redox status following brain ischemia, but more sensitive indicators are needed in 
future investigations. 
 
2.3.3 PEM and other mechanisms 
       PEM may influence stroke outcome by influencing blood glucose (21-23) and GC 
concentrations (24). PEM, GC, and blood glucose may interact in a complicated manner 
to affect ischemic brain injury. Figure 2.2 shows the potential interactions.  
                 Ischemia                                                                     PEM 
 
  ↑GC                     ↑ Blood Glucose                      ↑GC                 ↓ Blood Glucose 
 
                              ↑ Brain Damage                                                     
        
Figure 2.2 The relationship of ischemia, PEM and brain damage. 
      For three decades, numerous studies have shown that elevated pre-ischemic glucose 
levels lead to exacerbated post-ischemic brain damage (161-163). Hyperglycemia has 
been reported in several brain ischemia models and is correlated with poor prognosis in 
ischemic stroke because elevated glucose levels lead to elevated intra-ischemic lactic acid 
levels and lactic acidosis, thus exacerbating brain damage (164). The incidence and 
degree of hyperglycemia has been related to the severity of acute stroke, higher hospital 
mortality as well as poor functional outcomes (162, 165-167). The underlying 
mechanisms by which hyperglycemia affects stroke outcome may involve inducing a pro-
oxidative and pro-inflammatory state that can cause direct neuronal toxicity. PEM has 
been shown in several studies to decrease serum glucose level (21, 23), while insulin has 
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been reported to be decreased to promote glucose homeostasis (24). Ischemia- induced 
hyperglycemia could also be a stress response with activation of the hypothalamo-
hypophyseal-adrenal axis, which leads to an increase in cortisol and catecholamines (166). 
Hyperglycemia is also known to be associated with inflammation and oxidative stress 
(166). Glucose treatment results in a direct increase in NFκB binding activity in 
mononuclear cells contrary to water or alcohol (168). 
      PEM may also influence ischemic brain injury by increasing GC concentration. A 
high level of GC is seen in response to acute deficits of protein and energy (24). Blood 
cortisol in acutely protein-energy malnourished children (169) and serum corticosterone 
concentration in acutely protein energy malnourished young adult rodents (170, 171) 
range from 1.3 to 6-fold the concentration found in matched healthy subjects. Mice on a 
protein-free diet for 7 days also showed significantly impaired macrophage function 
mediated by elevated serum GC levels (171). Increased GC concentration in PEM may be 
detrimental to stroke outcome. High GC levels have been associated with cognitive 
dysfunction and severity of hemiparesis after stroke, and may predict mortality (172-174). 
GCs increase neuron loss (25), and expression of many cytokines receptors are potently 
upregulated by GCs. Membrane bound receptors for IL-1, IL-2, IL-4, IL-6, IFN-γ, and 
TNF-α are induced by GCs on several cell types (25, 175-177). These studies had not 
provided evidence that increased GCs was due to PEM, and thus further studies should be 
investigated in the context of stroke and PEM.  
       GCs are well known to affect NFκB activation. The hippocampus contains a high 
density of GC receptors (GR) (178), which can bind to activated NFκB in the nucleus. 
GR can also switch on IκBα gene expression (179). Increased production of IκBα binds 
to NFκB in the cytoplasma, preventing its translocation and activation. In contrast to my 
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hypothesis, decreased peritoneal macrophage NFκB translocation in response to 
lipopolysaccharide stimulation has been demonstrated in protein-deficient mice and 
suggested to be linked to increased circulating GCs levels (179).  
 
2.4 Animal Models of Stroke 
      The literature describes a vast number of different approaches to studying cerebral 
ischemia. These experimental models are designed to mimic the cellular and molecular 
events that take place in the brain after ischemic insults. An ideal animal model would 
closely mimic human stroke from all aspects, including complex physiology. These 
elements are needed to ensure reproducibility of ischemic insults and to make correct and 
statistically valid conclusions (180). Rodents are the most widely used animals. They 
share many features of brain vascular anatomy and physiology in common with the 
human, and they are relatively inexpensive and easy to work with. The two most widely 
used types of animal models of cerebral ischemia are focal ischemia and global ischemia. 
 
2.4.1 Focal ischemia 
      Focal ischemia is a model resulting in reduction of local blood flow in a defined area 
of the brain. Focal ischemia is divided into techniques that allow for reperfusion of the 
ischemic tissue (transient focal cerebral ischemia) and those without reperfusion 
(permanent focal cerebral ischemia) (181). MCAO is the model mostly widely used and 
can be achieved in many ways including embolism, endovascular filament (transient or 
permanent), and permanent and transient transcranial MCAO (181, 182). Focal ischemia 
is popularly used, since it mimics the majority of ischemic strokes in people (182, 183). 
The severity of the insult is controlled by varying the occlusion time. Another essential 
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feature of this model is that ischemic damage, rather paradoxically, progresses for days 
and even weeks after the restoration of the blood flow (183). The reperfusion injury is 
also well characterized for this model. However, this model relies on invasive and 
traumatic surgical procedures, requiring skillful techniques to reproduce the ischemic 
damage, and thus it often produces variable results (181). 
 
2.4.2 Global ischemia 
      In glocal ischemia, in contrast to focal ischemia, blood supply to the whole brain is 
stopped. It could be either transient or permanent (182). Global brain ischemia most often 
occurs in the clinical setting as a result of cardiac arrest, which results in cessation of 
systemic blood circulation, hypotension and hypoperfusion of the brain (37). While 
experimental global ischemia models have been criticized for mimicking cardiac arrest 
rather than clinical ischemic stroke, they share many of the same pathophysiological 
mechanisms and cause more consistent neuronal damage (182). The pathophysiological 
mechanisms of interest in this thesis, oxidative stress (17, 62, 184), NFκB activation (8), 
and inflammation (8) are all present in global ischemia. Models of global ischemia have 
been applied in several mammals such as cats (185, 186), rats (187) and gerbils (188) as 
well as in primates (161). There are several ways to produce global cerebral ischemia. 
The major ones in rodents are the two-vessel occlusion (hypotension and bilateral 
common carotid artery occlusion) and four-vessel occlusion (common carotid and 
vertebral artery occlusion) in the rat, decapitation, and either unilateral or bilateral 
common carotid artery occlusion (BCAO) in the gerbil (182, 189-191). 
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2.4.3 BCAO in Mongolian gerbils 
      The Mongolian gerbil has been used widely because of its unique vasculature which 
lacks a circle of Willis (183). Due to the absence of posterior communicating arteries 
between vertebral and internal carotid arteries, global ischemia is produced simply by 
BCAO (192). Delayed neuronal cell death occurs selectively in highly vulnerable brain 
regions such as neocortical layers, dorsomedial striatum and, perhaps most importantly, 
in the CA1 region of the hippocampus (188, 193-195). Well-characterized both 
histologically and functionally, with behavioral testing, and without any complicated 
procedures, BCAO has typically resulted in reproducible and consistent ischemic brain 
damage (196-200). When the brain temperature is controlled at normothermic levels 
during ischemia, the BCAO gerbil model results in 75%-90% delayed CA1 neuron death 
with 3 and 5 min occlusions respectively without any sign of post-ischemic seizures (199, 
201, 202). Functional abnormalities have been well established following global ischemia 
in the gerbil model (181, 197, 200, 201, 203).  In keeping with the present thesis, 
oxidative stress, inflammation, and NFκB activation have been shown in the brain by this 
model of ischemia (8, 17, 62, 184). 
      However, two important recent studies have demonstrated that a significant 
proportion of gerbils from the major North American suppliers no longer have an 
incomplete circle of Willis, causing variability in neuronal damage after occlusion. Using 
both histological and behavioral testing, gerbils from Charles River showed a high 
incidence (22.8% with bilateral and 38.6% with unilateral anastomoses) of posterior 
communicating arteries. Behavioral indices of CA1 ischemic injury, including increased 
locomotion and habituation deficits, were also significantly attenuated in the Charles 
River gerbils (204). Seal et al (205) also demonstrated that ischemic injury was markedly 
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attenuated in the hippocampus of gerbils when posterior communicating arteries were 
greater than 50µm in diameter. These posterior communicating arteries, ranging from 19 
to 125 μm in diameter, were reported in 90% of gerbils from Charles River and Harlan 
Sprague-Dawley, the only two North American vendors of Mongolian gerbils for 
laboratory use. This evidence is consistent with higher than expected variability in 
neuronal damage in the gerbil global ischemia model in a previous study from our 
laboratory (17).  
      The high prevalence of posterior communicating arteries and their profound effect on 
attenuating hippocampal injury is causing investigators to adopt other models or modify 
this model. Since complete ischemia causes persistent hyperactivity apparent for even 
three days postischemia (198, 199), monitoring post-ischemic activity can be used as an 
indicator of complete ischemia. This strategy was used during the course of this thesis. 
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CHAPTER 3 
METHODOLOGY 
3.1 Experiment 1  
3.1.1 Animals and Diets 
        Adult male Mongolian gerbils (Charles River Canada, QC, Canada), age 11-12 
weeks, were acclimated for 4-7 days, and randomly assigned to adequate protein (CON, 
containing 12.5% protein as casein) or low protein diet (PEM, containing 2% protein as 
casein) (Dyets Inc., Bethlehem, PA, USA). The diet was modified from the AIN-93M 
rodent diet (206) and does not contain the antioxidant tertiary-butylhydroquinone (Table 
3.1). Gerbils fed a 2% protein diet voluntarily decrease their food intake, which results in 
a mixed PEM (17). Animals were housed in groups of three at 22°C with a 12 hr 
light/dark cycle in shoebox cages with CareFRESH (Absorption Corp, Bellinghem, WA, 
USA) bedding and with free access to food and water. Weekly body weights and daily 
food intakes were monitored during 28 days of feeding time. All animal care and 
procedures followed the Canadian Council on Animal Care guidelines and were approved 
by the University of Saskatchewan Committee on Animal Care and Supply. 
 
3.1.2 Surgical Procedures 
        After four weeks on their diets, the animals were subjected to either global ischemia 
or sham surgery, resulting in four experimental groups: control diet with sham surgery 
(CON-Sham, n=3), control diet with global ischemia (CON-Isch, n=6), PEM with sham 
surgery (PEM-Sham, n=3), PEM with global ischemia (PEM-Isch, n=6). Global ischemia 
was achieved with five minute bilateral carotid artery occlusion under 1.5%-2% 
isoflurane anesthetic with 1L/min O2. The common carotid arteries were isolated through 
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Table 3.1 Modified AIN-93M Rodent Diet 
Component Adequate protein
§
 (Control, CON) 
g/kg 
Low protein§§ (PEM)
g/kg 
Vitamin free casein 140 22.4 
L-cystine 1.8 0.29 
Sucrose 100 100 
Cornstarch 465.7 543.049 
Dextrinized Cornstarch 155 181.001 
Soybean oil 40 40 
Cellulose 50 50 
Mineral mix* 35 35¶
Calcium phosphate dibasic 0 12.4 
Calcium carbonate 0 3.36 
Vitamin mix† 10 10 
Choline bitartrate 2.5 2.5 
§ Control diet was formulated to contain 12% protein, 10% fat, 78% carbohydrate. 
§§ PEM diet was formulated to contain 2% protein, 10% fat, 88% carbohydrate. 
* AIN-93M mineral mix (206). 
¶ AIN-93M modified mineral mix: calcium and phosphorus deleted, potassium 
citrate·H2O increased from 28 to 226.55g/kg, sucrose increased from 209.806 to 618.256 
g/kg mineral mix. 
† AIN-93M vitamin mix (206).  
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a ventral midline incision. A surgical silk thread was passed under both arteries to allow 
gentle lifting of the artery. Core body temperature was monitored with a rectal probe and 
maintained at 37 ± 0.5°C with a homeothermic blanket (Harvard Apparatus Canada, 
Saint-Laurent, QC, Canada). Tympanic temperature was monitored intraischemically by 
inserting a fine temperature probe (Barnant Type T Digi-Sense Thermometer, Barrington, 
IL, USA) through the tympanic membrane. Tympanic temperature was maintained at 
36.5 ± 0.2°C by a blanket (Global Medical Products Inc., Burlington, ON, Canada) 
circulating with warm water wrapped around the gerbil’s head. When brain temperature 
was stable at 36.5°C, two 8 x 1.5mm micro-aneurysm clips (World Precision Instruments, 
Inc., Sarasota, FL, USA) were applied to both common carotid arteries for five minutes to 
block the blood flow. The blockage was confirmed visually. After removal of the clips, 
carotid artery reflow was again verified visually and the incision was closed. Sham 
surgery procedures were similar; arteries were isolated from other tissue by silk thread, 
but not occluded, and then released. Animals were all placed under a warm lamp for 2 hr 
to recover. As they recovered, they could choose to stay under the lamp or not. Animals 
were then returned to the shoebox cage to be monitored for postischemia activity.  
 
3.1.3 Behavioral Monitoring 
        The model of global ischemia relies on our gerbil supply consistently lacking a 
complete circle of Willis. However, a recent study by Laidley and Corbett (2005) shows 
that a significant proportion of gerbils from Charles River no longer have an incomplete 
circle of Willis, causing variability in neuronal damage after ischemia. Since complete 
ischemia causes persistent hyperactivity apparent for even three days postischemia (196, 
199), one way to screen out animals with undesirable brain vasculature is to monitor 
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activity continuously post-ischemia. Therefore we monitored activity for 20hr following 
surgery using the Opto-M3 Activity Meter (Columbus Instruments, Columbus, OH, 
USA). 
       This instrument supports a modular multi-channel activity monitoring and a variety 
of optical beam sensors. The sensors are mounted around a standard cage by bolting the 
ends of the sensors to four corner brackets. Each sensor pair includes a detector and 
emitter. Two sensor pairs are required for each monitoring station, so that 2-dimensional 
monitoring is accomplished as infrared light beams (wavelength = 875 nm) pass through 
the cage. There are 16 light beams, spaced 1 inch apart and each beam is 0.32cm in 
diameter. Animal motor activity was measured by counting the interruptions indicated by 
the sensors. The accumulated two-dimensional total counts were recorded every 15 
minutes with computer software (The CI Multi-Device Software, Columbus Instruments, 
OH, USA). Activity monitoring started 2 hr after the surgery and lasted for 20 hr (for 
24hr or 72hr survival animals). Gerbils were then either humanely killed or returned to 
the animal care room. Gerbils taken to a 6hr survival time were monitored for 4 hrs only. 
        Criteria for complete ischemia were established as: 1) Activity had to be greater than 
3 standard deviation (SD) above the mean activity of sham animals. The mean + 3SD was 
chosen statistically as it would encompass greater than 99% of the sham population (207).  
Mean (± SD) activity of sham animals in our laboratory is 190 ± 155 counts/20hr (n=30, 
combined data from experiments of J.Ji and M.Harmon). Both PEM and CON shams 
were included in deriving this value because there was no significant effect of diet on 
activity by a two-factor ANOVA (p=0.897) and there was no diet-ischemia interaction 
(p=0.782). 2) This hyperactivity had to be sustained throughout the 20hr period because it 
has been demonstrated that neuroprotective treatment reduces the period of hyperactivity 
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(198). Although no fixed tissue was available from my study for histological assessment, 
my laboratory co-worker (Monique Harmon), using an identical experimental design, 
assessed hippocampal damage histologically and validated that our activity screening 
procedure correctly identifies 84.6% of animals with respect to complete forebrain 
ischemia. 
 
3.1.4 Serum Cortisol and Serum Glucose 
        Since PEM may decrease serum glucose (21-23) and increase serum cortisol (24), 
and both these factors have been reported to influence stroke outcome (25, 26), blood 
samples were collected at 6hr following ischemia to measure these two physiological 
variables. Blood samples were centrifuged (Eppendorf Centrifuge 5417C, Westbury, NY, 
USA) at 1500 x g for 10 minutes after being clotted at room temperature. Serum samples 
were transferred to 500μl microcentrifuge tubes and stored at -80°C. Blood samples that 
were hemolyzed as assessed by visual inspection were excluded. Serum glucose and 
cortisol were analyzed by Prairie Diagnostic Services, College of Veterinary Medicine, 
University of Saskatchewan. Serum glucose was analyzed by the hexokinase method 
spectrophotometrically at 505 nm (Roche/Hitachi 704/911/912, Roche Diagnostics 
Corporation, IN, USA). Serum cortisol was measured by radioimmunoassay designed to 
measure total cortisol (Coat-A-Count Cortisol Kit, Diagnostic Products Corporation, LA, 
CA, USA). 
 
3.1.5 NFκB Activation 
3.1.5.1 Preparation of Hippocampal Nuclear Extracts  
         Animals were perfused with heparinized saline by intracardiac injection at 6hr, 24hr 
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and 72hr postischemia. Brain hippocampus was dissected on ice. The nuclear extraction 
method was modified from Xu et al.(208). Approximately 0.05g of hippocampal tissue 
for each animal was homogenized in 0.5ml 0.1% phosphate buffered saline using a 
Brinkmann Polytron Model PT10-35 (Rexdale, ON, Canada) buffer for 5 strokes, with 
each stroke lasting 5seconds. Then each sample was centrifuged (Eppendorf Centrifuge 
5403, Westbury, NY, USA) at 600 x g for 10 min and the pellet was resuspended in 
0.5ml buffer A  at pH 7.9 (10 mmol/L HEPES buffer,10 mmol/L KCl, 1.5 mmol/L MgCl2, 
0.1 mmol/L dithiothreitol, 1 mmol/L phenylmethylsulphonyfluoride). The mixture was 
incubated on ice for 10 min and centrifuged again at 600 x g for 10 min. The pellet was 
again resuspended in 0.3 ml buffer A to which 0.05% Nonidet P-40 was added. This was 
homogenized again for 5 strokes at 5seconds per stroke to lyse the nuclei. The sample 
was then centrifuged again at 600 x g for 10 min and resuspended in 0.5 ml buffer C at 
pH 7.9 (5 mmol/L HEPES, 25% glycerol, 1.5 mmol/L MgCl2, 0.4 mmol/L EDTA, 0.3 
mol/L NaCl). Finally, it was mixed well and incubated on ice for 30min before being 
centrifuged at 14000 x g for 30 min. The nuclear extract (the supernatant) was then 
aliquoted to microcentrifuge tubes and stored at -80°C. 
 
3.1.5.2 Protein Analysis 
        Total protein concentration of hippocampal nuclear extracts was determined by the 
bicinchoninic acid (BCA) assay (209). First, the stock protein standard was prepared 
using bovine serum albumin and deionized distilled water (DD-H2O). Working protein 
standards were then diluted in DD-H2O to the following concentrations: 0, 0.0625, 0.125, 
0.25, 0.5, and 1 mg/ml. Standards (to make a standard curve), blanks and unknowns were 
run in triplicates. Cupric sulfate pentahydrate (BDH Chemicals, Toronto, Canada) 
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solution (4%) was prepared. The working BCA solution contained 1 part cupric sulfate 
solution and 5 parts BCA.  One ml BCA working solution was added to each 100 μl 
standard, blank or unknown sample. The final dilution of the brain nuclear extracts for 
the BCA assay was 1:200. The mixture was incubated at 37°C for 30min and allowed to 
cool down to room temperature. The concentration was measured using a 
spectrophotometer at 560 nm (Shimadzu, UV-265, UV-visible Recording 
Spectrophotometer, Columbia, MD, USA). The protein concentration of the sample was 
calculated from the standard curve by linear regression analysis.  
 
3.1.5.3 EMSA Analysis and Semiquantification 
        NFκB activation was analyzed by EMSA using a gel shift NFκB family kit (Active 
Motif, Carlsbad, CA, USA). Radioactive labeling of oligonucleotide probe was achieved 
by adding 2 μl unlabeled wild-type oligonucleotide probe which contained a consensus 
sequence 5′-GGGGTATTTCC-3′, 5 μl of 5X T4 Kinase buffer, 4 μl (40 μCi) [γ-32P]-ATP, 
1 μl of T4 polynucleotide kinase (Invitrogen, Carlsbad, CA, USA), and 8 μl DD-H2O to a 
final volume of 20 μl. The probe was incubated at 37°C for 30 min and 5 μl of 1% 
SDS/100mM EDTA solution was added to stop the kinase reaction. Radioactivity of the 
labeled probe was determined by measuring 1μl of purified probe in a scintillation 
counter (Beckman  LS6500 multi-purpose scintillation counter, Fullerton, CA, USA). 
The activity of the probes had to be greater than 1x105 c.p.m/μl. 
        The extract premix was prepared by adding 5 μl DD-H2O, 4 μl buffer B (Active 
Motif, Carlsbad, CA, USA), 2 μl stabilizing solution D (Active Motif, Carlsbad, CA, 
USA), and 5 μl nuclear extracts on ice with gentle mixing by pipetting. The mixture was 
incubated for 20 min at 4°C. While incubating, probe premix was prepared by adding 2 
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μl DD-H2O, 2 μl buffer C, 1 μl buffer D and 1μl labeled oligonucleotide probe. The probe 
premix was then added to pre-incubated extract premix, mixed well and incubated for 20 
min at 4°C. 
        For EMSA detection, the entire content of premixed probe (6μl) and premixed 
extract (16 μl) were mixed and loaded onto a 5% polyacrylamide 
(acrylamide:bisacrylamide, 38:2) gel and pre-cooled to 4°C in Tris-Glycine 
electrophoresis buffer containing 24.8 mM Tris, 190 mM glycine and 1 mM EDTA. Gel 
components included 5% polyacrylamide, 20% buffer containing 124 mM Tris, 950 mM 
glycine, 5 mM EDTA, 10% ammonium persulfate, and 1% TEMED (N,N,N',N'-
Tetramethylethylenediamine) (pH ~8.3). Sixteen cm plates with 10 wells on each gel 
were used in the electrophoresis apparatus EC105 (EC Apparatus Corporation, Holbrook, 
NY, USA). The gels were run at 100V for 1 hr or until the loading buffer (0.25% 
bromophenol blue, 0.25% xylene cyanol, 30% glycerol) reached the bottom third of the 
plates. The gels were then dried by a gel dryer (Labconco Gel Dryer, Kansas City, MO, 
USA), exposed to Kodak X-OMAT film (Eastman Kodak Company, Rochester, NY, 
USA),  and stored at -80°C for 24 hr.  
        Bands corresponding to the binding reaction between activated NFκB and labeled 
oligonucleotide probe were detected by autoradiography using a densitometry system 
(Alphalmager system, Alpha Innotech, San Leandro, CA, USA). The results were 
expressed as a ratio which was calculated as the density of the sample from an 
experimental group per μg protein divided by the density of a sample from the reference 
group per μg protein. Each gel contained a sample from an animal on control diet without 
exposure to any type of surgery, which was designated as the reference group. This ratio 
was used to decrease the variability between gels, radioactivity of labeled probe and film 
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development. All samples were analyzed using the same probe, and all runs were 
completed over a 2-day period. Six gels were run, and every gel contained 10 samples. In 
order to keep these variables controlled, the following number of samples were analyzed 
for all three timepoints (6hr, 24hr, 72hr): PEM-Isch (n=6); CON-Isch (n=6); PEM-Sham 
(n=2); CON-Sham (n=2). 
 
3.1.6 Statistical Analysis 
           All statistical analyses were conducted using SPSS 12.0 for windows (SPSS Inc., 
Chicago, IL, USA). Body weight and feed intake pre-ischemia were analyzed by 
unpaired Student’s t-test. Activity data for assessing complete ischemia were analyzed to 
ensure there were no diet effects or diet-ischemia interactions using two-factor ANOVA. 
Postischemia body weights and biochemical data were analyzed by two-factor ANOVA. 
Correlation of NFκB activation and activity was analyzed by Pearson’s Correlation 
Coefficient. Differences were considered statistically significant at p<0.05. All data were 
presented as mean ± SEM. 
 
3.2 Experiment 2 
        Since increased hippocampal NFκB activation was observed in PEM-Sham animals 
in Experiment 1, a second experiment was designed to investigate whether PEM 
increases NFκB activation in the hippocampus independent of sham surgery. Male 
Mongolian gerbils of the identical strain and age as used in Experiment 1 were randomly 
assigned to either CON diet or PEM (n=6 for each group) for 28 days but did not receive 
any surgical intervention. Tissue perfusion was at a timepoint equivalent to 6 hr 
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postischemia. Nuclear extracts were prepared from hippocampus and EMSAs were 
performed for NFκB activation as described previously.  
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CAPTER 4 
RESULTS 
4.1 Experiment 1 
4.1.1 Body Weight and Feed Intake 
         Initial and final body weights, 28-day body weight change, and total feed intake are 
presented in Table 4.1. The initial body weight was not significantly different between 
CON and PEM groups. After the 28-day period of feeding, the control group gained on 
average 4.9g body weight and the PEM group lost on average 7.4 g. The differences in 
final body weight and body weight change between the groups are significant (p<0.001). 
Average total 28-day feed intake per animal per cage is significantly different between 
the CON and PEM groups (p<0.001). 
Table 4.1 Body weight and feed intake prior to ischemia 
                  Parameter          CON         PEM 
Initial Body Weight (g) π 63.4 + 0.5 62.2 + 0.6 
Final Body Weight (g) π 68.3 + 0.6 54.7 + 0.8* 
28-Day Body Weight Change (g) π + 4.9 + 0.5 - 7.4 + 0.7* 
Total 28-Day Feed Intake (g) λ 109.6 + 1.4 93.7 + 1.8* 
   Results in the table are shown as mean ± SEM.  
* Indicates significantly different from control group by unpaired T-test. CON or PEM 
designates animals on control diet or exposed to PEM, respectively.                                                               
π n = 36                                                                                                                                
λ n = 12 cages (3 animals/cage); presented as average intake/animal/cage. 
 
            Following ischemia, there was a significant effect of diet (p<0.001) on body 
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weight but no significant effect of ischemia (p=0.260, 0.379, 0.124, at 6hr, 24hr, 72hr 
respectively) or interaction between surgery and diet at any timepoint (p=0.373, p=0.806, 
p=0.635 at 6hr, 24hr, 72hr respectively) (Table 4.2). All experimental groups had weight 
loss during the 72 hr period following surgery except the CON-Sham group. Data on feed 
intake are shown in Figure 4.1 for animals taken to 24hr and 72hr timepoints 
postischemia. These data are shown descriptively because there was an insufficient 
sample size to undertake statistical analysis. Feed intake was decreased at 24hr 
postischemia and returned to preischemic levels by 72 hr.  
Table 4.2 Pattern of body weight post-ischemia 
Timepoint CON-Sham CON-Isch PEM-Sham PEM-Isch 
6hr 66.4 ± 0.8 66.1 ±1.0 56.3 ± 1.2* 54.1 ± 0.8* 
24hr 65.9 ± 0.7 64.8 ± 1.8 55.5 ± 1.8* 53.5 ± 1.2* 
72hr 66.2 ± 1.2 62.6 ± 1.6 51.4 ± 1.6* 49.5 ± 1.4* 
 Results in the table are shown as mean ± SEM, n=6 for each ischemic group, n=3 for 
each sham group. *PEM significantly decreased body weight at all timepoints (2-factor 
ANOVA, P<0.001). 
 
4.1.2 Serum Glucose 
        Serum glucose concentration at 6 hr postischemia is shown in Figure 4.2. There was 
no significant effect of diet (p=0.242) or ischemia (p=0.359) on serum glucose and no 
interaction between diet and ischemia (p=0.844). Table 4.3 shows data for serum glucose 
concentration when data for animals with incomplete ischemia are removed. 
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Figure 4.1 Pattern of postischemic feed intake. Average feed intake/day was calculated as 
total feed intake/day/number of animals in the cage. n =2 cages (3 animals /cage) for each 
ischemia group, n=1 cage (3 animals /cage) for each sham group. Animals taken to a 24hr 
endpoint are shown in A and 72hr endpoint data are shown in B. CON-Sham: sham 
animals with control diet; CON-Isch: ischemic animals with control diet; PEM-Sham: 
sham animals with PEM; PEM-Isch: ischemic animals with PEM. 
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Figure 4.2 The effect of PEM and ischemia on serum glucose concentrations at 6hr 
postischemia. Results are presented as mean ± SEM; n=6. No significant effects of 
treatments were found by a two-factor ANOVA (p>0.05). CON-Sham: sham animals with 
control diet; CON-Isch: ischemic animals with control diet; PEM-Sham: sham animals 
with PEM; PEM-Isch: ischemic animals with PEM. 
 
Table 4.3 Individual serum glucose concentrations at 6 hr postsurgery for gerbils with 
sham surgery or complete forebrain ischemia.  
 
Serum Glucose (mmol/L) 
CON-Sham CON-Isch PEM-Sham PEM-Isch 
7.2 5.3 5.5 5.5 
7.4 4.9 5.4 5.6 
6  6.7 6.7 
6.5  5.4 6.3 
5.8  5  
4.8  6  
 
 
 46
4.1.3 Serum Cortisol 
       Serum cortisol concentration at 6hr postischemia is shown in Figure 4.3. There was 
no significant effect of diet (p=0.878) or ischemia (p=0.702) on serum cortisol and no 
interaction was found between ischemia and diet (p=0.832). Table 4.4 shows data for 
serum cortisol concentration when data for animals with incomplete ischemia are 
removed. 
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Figure 4.3 The effect of PEM and ischemia on serum cortisol concentration at 6hr 
postischemia. Results are mean ± SEM; n=6. No significant effects of treatments were 
found by a two-factor ANOVA (p>0.05). CON-Sham: sham animals with control diet; 
CON-Isch: ischemic animals with control diet; PEM-Sham: sham animals with PEM; 
PEM-Isch: ischemic animals with PEM. 
 
4.1.4 Activity Monitoring 
       Activity criteria for complete ischemia were set at >3SD above mean activity of 
sham animals (n=30) as described in the Methods section. This was calculated as 654 
mean counts/20 hr. In addition, hyperactivity had to be present for the entire monitoring 
period. 45.8% (11/24) of occluded animals passed this criteria. 
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Table 4.4 Individual serum cortisol concentrations at 6 hr postsurgery for gerbils with 
sham surgery or complete forebrain ischemia.   
 
Serum Cortisol (µmol/L)   
CON-Sham CON-Isch PEM-Sham PEM-Isch 
1.1 1.6 3.2 5.5 
4.6 3.0 3.7 5.6 
4.9  3.2 6.7 
1.3  1.1 6.3 
3.6  4.3  
4.1  3.0  
 
       Figure 4.4 shows representative major patterns of activity obtained when activity was 
monitored over 20hr as an indicator of complete ischemia. Sham animals showed very 
low activity over the entire period. The pattern of activity seen in animals subjected to 
ischemia can be divided into three subgroups. 1) A group showing persistent 
hyperactivity which indicates complete ischemia. 2) A second group showing low activity 
representative of incomplete ischemia. 3) The third subgroup had hyperactivity which 
was not persistant over the entire time of monitoring, also representative of incomplete 
ischemia.         
       Table 4.5 shows the activity data obtained from individual animals in this experiment. 
The data from animal killed at 6 hr could not be analyzed because 4 hr is not a 
sufficiently long period to assess persistent hyperactivity.  
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 Figure 4.4 Pattern of activity postischemia. 
Table 4.5 Activity monitoring on individual animals to assess complete ischemia 
Activity (Mean Counts/20hr) 
24hr CON-Isch 24hr PEM-Isch 72hr CON-Isch 72hr PEM-Isch 
72 1015* 170 46 
2002* 224 2348* 475 
1961* 1000* 179 1306* 
31 2974* 123 502 
234 526 904* 2056* 
107 999* 179 1367* 
* indicates the animal passed criteria >mean + 3SD for sham animals (=654 mean 
counts/20 hr) and the activity was persistent over 20hr. 
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4.1.5 NFkB Activation Analysis 
4.1.5.1 Protein Analysis of hippocampal Nuclear Extracts 
         Total protein concentrations of nuclear extracts are shown in Table 4.6. There was 
no significant effect of PEM (p=0.210, 0.108, 0.972 at 6hr, 24hr, and 72hr respectively) 
on protein concentration. Ischemia significantly increased protein concentration at 24 hr 
(p=0.013) but not at 6 hr (p=0.065), and there was no effect at 72 hr (p=0.854). There was 
no interaction between diet and ischemia at any timepoint. 
Table 4.6 Protein concentration of hippocampal nuclear extracts at different timepoints 
post-ischemia (mg/ml) 
 CON-Sham CON-Isch PEM-Sham PEM-Isch 
6 hr 3.2 ± 0.4 2.0 ± 0.3 2.2 ± 0.4 2.0 ± 0.3 
24 hr 1.7 ± 0.2 2.5 ± 0.2* 2.3 ± 0.3 2.6 ±0.1* 
72 hr 2.1 ± 0.4 2.2 ± 0.2 2.3 ± 0.3 2.0 ± 0.3 
Protein concentrations in the table are shown as mean ± SEM. n=3 for each sham group; 
n=6 for all ischemic groups except n=5 for 24 hr CON-Isch group. Pooled mean ± SEM 
for ischemic groups are 2.0 ± 0.2, 2.6 ± 0.1, and 2.1 ± 0.2 mg/ml at 6 hr, 24 hr, and 72 hr 
respectively; pooled mean ± SEM for sham groups are 2.7 ± 0.3, 2.0 ± 0.2, and 2.2 ± 0.2 
mg/ml at 6 hr, 24 hr, and 72 hr respectively. * Protein concentration was increased by 
ischemia (p=0.013). 
 
4.1.5.2 NFkB Activation as Assessed by EMSA 
       Figure 4.5 shows representative autoradiograms of NFκB activation in hippocampal 
nuclear extracts measured by electrophoresis mobility shift assay (EMSA). Generally, 
activation of NFκB appeared to be more pronounced as a result of PEM than from global 
ischemia. 
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Figure 4.5 Representative autoradiograms of NFκB activation in hippocampal nuclear 
extracts measured by EMSA. A, Effect of ischemia on NFκB activation at various times 
postischemia. Times postischemia are 6 hr, lanes 1 and 2, 24 hr, lanes 3 and 4, and 72 hr, 
lanes 5 and 6; Lane 1 = CON-Isch; Lane 2 = PEM-Isch; Lane 3 = CON-Isch; Lane 4 = 
PEM-Isch; Lane 5 = CON-Isch; Lane 6 = PEM-Isch. B, Effect of PEM on NFκB 
activation. Times postsurgery are 6hr, lanes 1-2, 24hr, lanes 3-6; Lane 1 = CON-Sham; 
Lane 2 = PEM-Sham; Lane 3 = CON-Sham; Lane 4 = PEM-Sham; Lane 5 = CON-Isch; 
Lane 6 = PEM-Isch. 
 
4.1.4.3 Semi-quantification of EMSA Results 
       At 6 hr postsurgery, PEM significantly increased NFκB activation (p=0.014) (Figure 
  4.6). Ischemia didn’t significantly affect NFκB activation (p=0.169) and there was no 
interaction between diet and ischemia (p=0.270). Because of the pronounced effects of 
PEM on NFκB activation independent of ischemia and the small sample size, those 
animals with incomplete ischemia were included in the analysis. 
       At 24hr postsurgery, there was a trend for PEM to increase NFκB activation (p=0.097) 
(Figure 4.7). There was no significant effect of ischemia (p=0.644) or interaction between 
diet and ischemia (p=0.360). Table 4.7 shows data for NFκB activation when data for 
animals with incomplete ischemia are removed. 
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 Figure 4.6 The effect of PEM and ischemia on NFκB activation in hippocampus at 6 hr 
postsurgery. Results are presented as mean ± SEM; n=6 for each ischemic group and n=2 
for each sham group. Δ There is a significant effect of diet by a two-factor ANOVA 
(p=0.014). * Arbitrary density unit of the experimental sample/μg protein divided by the 
arbitrary density unit of the reference sample/μg protein. 
Table 4.7 Individual hippocampal NFκB activation ratios at 24 hr postsurgery for gerbils 
with sham surgery or complete forebrain ischemia.   
 
 
NFκB activation (Ratio)* 
CON-Sham CON-Isch PEM-Sham PEM-Isch 
0.71 2.31 2 3.89 
1.3 1.95 1.33 3.28 
   1.35 
   1.51 
 * Arbitrary density unit of the experimental sample/μg protein divided by the arbitrary 
density unit of the reference sample/μg protein. 
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Figure 4.7 The effect of PEM and ischemia on NFκB activation in hippocampus at 24 hr 
postsurgery. Results are presented as mean ± SEM; n=6 for PEM-Isch group, n=5 for 
CON-Isch group, n=2 for each sham group. There was a trend for PEM to increase NFκB 
activation by a two-factor ANOVA (p=0.097). * Arbitrary density unit of the 
experimental sample/μg protein divided by the arbitrary density unit of the reference 
sample/μg protein. 
 
        At 72 hr postsurgery, the increased NFκB activation caused by PEM appeared to be 
absent by a two-factor ANOVA analysis (Figure 4.8) (diet, p=0.189; ischemia, p=0.762; 
interaction between diet and ischemia, p=0.983). However, these data are technically 
flawed because too much radioactivity was added to the probe, and the films were 
saturated, resulting in loss of sensitivity to detect differences in NFκB activation. 
 
4.1.6 Correlation of NFκB activation and Postischemia Activity 
        Correlation data between NFκB activation and postischemia activity from the 
animals taken to a 24 hr postischemia endpoint are shown in Figure 4.9. There was no 
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significant correlation between NFκB activation and activity level in ischemic animals 
fed control diet as detected by a Pearson’s Correlation Coefficient (p=0.132, R2=0.764, 
n=5). The correlation was also not significant in ischemic animals with PEM (p=0.790, 
R2=-0.141, n=6). Similar analysis could not be performed for the other two timepoints. At  
6hr, accurate activity data could not be collected to access if hyperactivity was persistent. 
At 72 hr, the NFκB activation data were flawed due to saturation of the film. 
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Figure 4.8 The effect of PEM and ischemia on NFκB activation in hippocampus at 72 
hr postsurgery. Results are shown as mean ± SEM; n=6 for each ischemic group and 
n=2 for each sham group. There were no significant differences shown by a two-factor 
ANOVA (p>0.05). * Arbitrary density unit of the experimental sample/μg protein 
divided by the arbitrary density unit of the reference sample/μg protein. 
 
4.2 Experiment 2 
4.2.1 Body Weight and Feed Intake 
      The data on body weight and feed intake showed the same pattern as in the first 
experiment. The initial body weight was not significantly different between CON group 
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Figure 4.9 Correlation of NFκB activation and postischemia activity level at 24 hr 
postsurgery. ▲indicates the ischemic animals on control diet (n=5); ● indicates the 
ischemic animals with PEM (n=6). * Arbitrary density unit of the experimental 
sample/μg protein divided by the arbitrary density unit of the reference sample/μg 
protein. 
 
and PEM group (p=0.809) (Table 4.8). After the 28-day period of feeding, the CON 
group gained on average 4.3g body weight and the PEM group lost 7.1g. The difference 
in 28-day body weight and body weight change is significant (both p<0.001). Total 28-
day feed intake is also significantly different between CON and PEM animals (p<0.001). 
Table 4.8 Body weight and feed intake 
 CON PEM 
Initial Body Weight (g) π 62.8 ± 0.6 63.4 ± 0.4 
Day28 Body Weight (g) π 67.1 ± 0.9 56.4 ± 0.7* 
28-Day Body Weight Change (g) π + 4.3 ± 0.9 - 7.1 ± 0.7* 
28-Day Feed Intake (g) λ 105.1 ± 4.0 91.7 ± 3.1* 
Results in the table indicate mean ± SEM; * Indicates significantly different from control 
group by unpaired T-test. π n = 6,  λ n = 2 cages (3 animals/cage); presented as average 
intake/animal/cage. 
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4.2.2 NFκB Activation Analysis 
       Figure 4.10 shows that hippocampal NFκB activation was increased in PEM animals 
compared to CON animals even in the absence of sham surgery. Unlike the previous 
EMSA results which were presented as a ratio (relative to data from a reference animal), 
these data are shown as actual density per μg protein. The reason is that these data come 
from the reference animals and they were thus run on separate gels. PEM consistently 
increased NFκB activation when compared to the control animal run on the same gel. The 
variability is much higher than in Experiment 1 because of the inability to control for 
variability among gels, and thus the effect of PEM is not significant (p=0.320; n=4) by 
unpaired t-test. 
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Figure 4.10 The influence of PEM on hippocampal NFκB activation in the absence of 
sham surgery. The results are given as density units per μg protein. Each pair of values 
presents the results from one gel. ADU, Arbitrary density unit.  
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CHAPTER 5 
DISCUSSION 
       It has been previously shown in our laboratory that gerbils fed with 2% protein diet 
for 28 days have decreased feed intake, significant weight loss, decreased liver GSH, 
increased liver lipid concentration (17) and decreased serum albumin concentration (210), 
indicating that a moderate PEM was achieved. Consistently, using the same model in the 
current study, gerbils fed 2% protein had the same magnitude of decrease in feed intake 
and weight loss. Gerbils appeared normal with no signs of sparse hair, edema, diarrhea or 
other signs of severe protein deficiency. Our model is distinguished from two other 
models of PEM. One is a milder protein deficiency induced by feeding 7.5% protein in 
which voluntary feed intake is not decreased (211, 212). The second is a severe PEM in 
which rats are fed a protein-free diet for two weeks, causing severe protein deficiency 
symptoms (213). Increased liver lipid in our model is consistent with a diet that supplies a 
relatively higher proportion of energy from carbohydrate than protein, causing decreased 
synthesis of the apolipoprotein required for transport of triglycerides out of the liver 
(214). Serum albumin is the protein in highest concentration in human blood and key to 
the regulation of the osmolality of blood. Due to its half-life of eighteen to twenty days, 
serum albumin is not necessarily decreased in early PEM (215). However, as severe 
protein depletion worsens, albumin and other serum protein decrease, resulting in 
reduced intravascular oncotic pressure and edema. The combination of decreased feed 
intake and body weight shown in this study combined with previous findings of increased 
liver lipid and decreased serum albumin indicate that our model is a combination of both 
protein and energy deficiency, which also can be characterized as marasmic kwashiorkor. 
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       PEM resulted in a loss of body weight at all times sampled during the post-ischemic 
period, and this did not differ between the PEM sham and PEM ischemic groups. This 
was seen in a previous study using the same model of global ischemia (146). The 
ischemic group fed control diet also lost weight following surgery. Because of the small 
sample size, post-ischemic feed intake was shown only descriptively. Feed intake 
appeared to decrease after surgery in all groups and return to pre-ischemic level by three 
days. Post-ischemic feed intake and weight loss in rodent surgical models of stroke are 
often not reported but are very important as they can exert effects on brain damage 
independent of the experimental factors being studied, and thus are potential confounding 
variables. 
       Our laboratory has previously shown that PEM impairs functional outcome up to 10 
days following global ischemia as measured by habituation in the open field. A subset of 
these animals also showed marked reactive gliosis that correlated with the functional 
impairment (17). Reactive gliosis is characterized by the hypertrophy of astrocytes and 
proliferation of both astrocytes and microglial cells around the injured region (216). 
These findings suggest that the relationship between undernutrition immediately after 
stroke and reduced survival, functional ability and living circumstances six months later 
detected by the FOOD Trial Collaboration may be causal (16). The findings also support 
those of another study demonstrating that stroke patients had a shorter hospital stay when 
fed within 72 hr of the ischemic insult (144).  
       The major objective of the current study was to identify a mechanism by which PEM 
impairs outcome following global ischemia. The reactive gliosis suggested an increased 
inflammatory response. Inflammatory mechanisms modulate the proliferation of reactive 
astrocytes (153), and microglia can produce toxic molecules including pro-inflammatory 
 58
cytokines and also reactive species including NO•, oxygen radicals and arachidonic acid 
derivatives (154). PEM had been shown to increase the inflammatory response in other 
studies. The inflammatory mediators, IL-6, C-reactive protein, and soluble receptors of 
TNF-α, were found to be greater in the plasma of PEM children (18). Since NFκB plays a 
central role in regulating the inflammatory response following ischemia (132), and 
protein-malnourished mice show increased activation of NFκB and increased 
transcription of its downstream genes, IL-1β and TNF-α, in liver when induced by 
lipopolysaccharide (20), we questioned if the effects of PEM on outcome in global 
ischemia could be linked to increased NFκB activation. 
       In this study, PEM caused a marked increase, independent of ischemia, in increasing 
NFκB activation in hippocampus at 6 hr following global ischemia (p=0.014) and a trend 
at 24 hr (p=0.097). This is the first report of PEM influencing NFκB activation in brain. 
The data collected at 72 hr post-ischemia were technically flawed, so it is not known if 
there is prolonged activation of the transcription factor. It is important to examine this in 
future studies because prolonged NFκB activation in PEM following ischemia could 
regulate secondary damage. Clemens et al (11) found that NFκB activation was increased 
in CA1 neurons at 72 h following global ischemia in rats. The persistent increase of 
NFκB activation at 72 h after ischemia may be due to the inability of these neurons to 
synthesize IκB because of the long-term inhibition of synthesis of many proteins that 
occurs after global ischemia. Global ischemia may also cause a prolonged inhibition of 
synthesis of protective factors in this area. Another possibility is that persistent NFκB 
activation induces production of pro-apoptotic proteins.  
       The findings that PEM increases NFκB activation after global ischemia suggest that 
protein-energy deficiency, if present at the time of stroke, will increase the inflammatory 
 59
response. Future studies should investigate the pro-inflammatory target genes that are 
regulated by NFκB to determine whether PEM enhances the inflammatory response 
following brain ischemia. For example, the cytokine, TNF-α, a mediator of several 
cellular and molecular mechanisms involved in the development of ischemic damage, 
directly promotes activation and proliferation of glial cells (217). By examining the TNF-
α expression using immunohistochemistry or enzyme-linked immunosorbent assay, it 
could be determined if the marked reactive gliosis observed following global ischemia in 
protein-energy malnourished gerbils (17) is linked to activated NFκB with associated 
upregulation of TNF-α production. Similarly, gene expression of IL-1β, ICAM-1, COX-2 
and iNOS are also regulated by NFκB and are good markers to investigate the 
inflammatory response following ischemia.       
       Although it was hypothesized that PEM would enhance NFκB activation stimulated 
by global ischemia, no interaction between PEM and global ischemia was observed in 
this study. This finding needs to be confirmed with further study because of several 
limitations of this study. The first was that an insufficient number of sham animals was 
included in the study. A second limitation is the variability introduced by the inconsistent 
severity of ischemia related to the presence of unilateral or bilateral posterior 
communicating arteries in some gerbils. Screening for hyperactivity identified that 54.2% 
of the study animals with bilateral carotid occlusion were exposed to incomplete ischemia. 
All occluded gerbils were included in the NFκB analysis because there was an obvious 
increase in NFκB activation seen across gels for samples from all protein-energy 
malnourished animals, regardless of ischemic severity. Although the correlation between 
NFκB activation and hyperactivity monitoring at 24 hr post-ischemia was not statistically 
significant for either the control or protein-energy malnourished animals, the correlation 
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was much higher in the control group (P=0.132) than in the PEM animals (P=0.780), 
supporting the idea that PEM might be an independent predictor of NFκB activation. 
With a larger sample size, it appears that the correlation between activity and NFκB 
activation might become significant in the control group only. However, this type of 
correlation analysis relies on the assumption that the relationship between ischemic 
severity and persistent hyperactivity is linear.  While hyperactivity is a good predictor of 
ischemic severity (198, 199), there are no data demonstrating that the relationship is 
linear.  It will be necessary to undertake further studies with large sample size and 
hyperactivity monitoring to screen out gerbils with incomplete ischemia to determine if 
PEM and ischemia interact or act independently to increase NFκB activation. 
       We also did not observe the elevated NFκB binding at 6 and 24  hr post-ischemia 
demonstrated by others in both focal and global ischemia (8-11, 129, 130). Domanska-
Janik et al (8) have observed NFκB binding as early as 3 hr and continuing up to 7 days 
in hippocampus after global ischemia in the gerbil. Clemens and coworkers (10, 11) 
found that neuronal NFκB immunoreactivity in the hippocampus was induced 6 hr after 
global ischemia and persisted for three days until apoptotic degeneration occurred in CA1 
neurons (10). Importantly, similar observations were obtained by Schneider and 
coworkers (130) in mice in which prominent p65 immunoreactivity was seen in the 
apoptotic neurons of the penumbral area 3 days after transient focal ischemia.  
       There are a number of reasons that might explain why we did not detect an increase 
in NFκB activation with ischemia. High variability in NFκB activation occurred 
following global ischemia, and this can be accounted for by the inclusion of animals with 
incomplete ischemia in which one expects to find attenuated NFκB activation. This is 
supported by Figure 4.7 which shows increasing but variable NFκB activation in the 
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ischemic group fed control diet. Furthermore, the unexpected high NFκB activation 
found in protein-energy malnourished sham animals and the small sample size for both 
sham groups made it more difficult to detect an increase in NFκB activation with 
ischemia in animals fed control diet.    
Whether NFκB activation is neurodegenerative or neuroprotective remains a 
controversial question. In studies of cerebral ischemia, there is evidence for both, 
although there is more evidence indicating that sustained NFκB activation is detrimental, 
leading to prolonged secondary damage (218).  This is supported by a large amount of 
research that revealed persistent NFκB activation following ischemia associated with 
increased cytokines (110, 111, 114) and iNOS (122), which promote neuronal death.  
However, it appears that NFκB is a signal transducer that has dual effects on the immune 
response (218). As previously reported (8, 219), we detected constitutive binding activity 
of NFκB in hippocampus of sham controls. Depending on the intensity and duration of 
the stimuli, low level and transient NFκB activation could be important and necessary as 
a key regulator for the innate immune response. This is supported by data showing that 
neuronal damage can be increased under conditions when NFκB activation is impaired. 
In hippocampus of p50 knockout mice, NFκB DNA-binding activity is decreased and 
neuronal damage has been reported to be increased after the administration of the 
excitotoxin kainate (220). However, this evidence is in apparent contrast to that of 
Schneider et al (130) in which p50 knockout mice had significantly reduced neural 
damage in response to cerebral ischemia. Future studies with longer survival times are 
needed to reveal the role of NFκB activation in ischemia.  Increased NFκB activation in 
hippocampus from protein-energy malnourished animals could be an explanation for an 
increased inflammatory response leading to the reactive gliosis previously reported in our 
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laboratory (17).  However, the current results do not explain the impaired functional 
outcome demonstrated in the protein-energy malnourished gerbils following global 
ischemia because enhanced NFκB activation is also present in protein-energy deficient 
gerbils exposed to sham surgery.  The latter animals showed normal habituation patterns 
in the open field (17).  
       The results of this study have been significantly hampered by the high proportion of 
animals detected by activity monitoring to have a partial or complete circle of Willis, 
which is known to cause high variability in hippocampal CA1 damage (204). As we 
described before, using our criteria of persistent hyperactivity over 20 hr as an indirect 
indicator of ischemic severity, 54.2% of animals exposed to bilateral carotid artery 
occlusion in this study showed incomplete ischemia.  This number compares quite well 
with the 61.4% reported by Laidley and coworkers when they used direct assessment of 
cerebral vasculature to identify bilateral or significant unilateral posterior communicating 
arteries in gerbils from Charles River (204). Our laboratory activity screening method has 
recently been shown by a co-worker in the laboratory to classify approximately ~85% of 
gerbils correctly when assessed against histological evaluation of hippocampal CA1 
neuron death (Monique Harmon, unpublished communication). Using the same 
experimental model, combined data from both experiments showed that PEM did not 
alter the hyperactivity (p=0.897) or interact with ischemia (p=0.782). This screening 
method is therefore useful for studying PEM and impaired outcome. However, it is not 
suitable for investigating treatments that improve ischemic outcome, since 
neuroprotective agents interfere with activity (198) and thus would confound the 
screening tool. Although this screening could be used to reduce inter-animal variability to 
an acceptable level, a more direct method with greater accuracy suggested by Laidley et 
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al (204), is to use laser Doppler flowmetry to ensure blood flow is reduced to an 
acceptable level in the brain region of interest.  Regardless of the method of screening, 
however, the need to screen out such a high proportion of animals will lead to 
unacceptably high cost and time required to complete an experiment. Unless a supply of 
gerbils bred to consistently lack posterior communicating arteries becomes commercially 
available, it is likely that the gerbil model of global ischemia will be abandoned by stroke 
researchers and replaced by either the 2-vessel occlusion or 4-vessel occlusion models of 
global ischemia in the rat. 
       After demonstrating that NFκB activation was also increased in hippocampus from 
protein-energy deficient gerbils exposed only to sham surgery, Experiment 2 was 
performed to determine if this was also the case in the absence of surgery.  Again, we 
found greater NFκB activation in hippocampus with PEM. These findings add further 
weight to those of Experiment 1, in which the sample size for sham animals was small.  
While unrelated to the subject of this thesis, this finding has important implications since 
PEM is still a global problem. In 2000, the WHO Global Database showed that the 
prevalence of PEM in children under five years of age in developing countries world-
wide was 32.5 % (221). In adults, PEM may occur secondary to many diseases (222). 
Our observation suggests that increased NFκB activation and inflammation may be a 
general feature of PEM.  It will be important to investigate the effect of PEM on NFκB 
activation in other tissues, such as liver, lung and kidney, so that the impact of PEM on 
the inflammatory response of the whole body can be revealed. Alternatively, the 
increased NFκB activation in PEM could represent a response to pre-surgery stress or 
anaesthesia. A survival time longer than 24 hr is needed to confirm whether PEM causes 
a sustained increase in NFκB activation or a short-term response to stress.  
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       The study results are also limited by the technical difficulty of running EMSA. While 
an EMSA provides good evidence for NFκB binding to DNA, semi-quantifying 
accurately with densitometry across different gels is difficult. Which dimers of NFκB are 
translocated has not been determined in this study which used gel shift methodology.  
This can be determined in future with supershift assays which employ the same 
techniques but with the addition of antibodies against the subunits of NFκB. A DNA-
binding ELISA could also provide a more quantitative approach to measuring NFκB 
activation and specific subunit translocation.  Future studies should also investigate 
whether PEM decreases the cytosolic inhibitor, IκB, which allows the increased NFκB 
translocation into the nucleus. Phosphorylation and degradation of IκBα has been shown 
to be involved in NFκB activation and deactivation in ischemia (104, 135). IκBα can also 
be measured by DNA-binding ELISA. 
       This study has not addressed the mechanisms by which PEM affects hippocampal 
NFκB activation. As described, PEM may affect the inflammatory response (18, 19, 150) 
and oxidative stress (17, 223), two key regulators of NFκB activation. There is a wide 
range of candidate molecules that could be responsible for the increase in NFκB 
activation. For example, as an inflammatory mediator, TNF-α is one of the stimuli that 
could be directly triggering NFκB activation since TNF-α levels have been found to be 
higher in plasma from protein-energy malnourished children (18). Thus, PEM may 
trigger NFκB activation through increasing TNF-α expression.  
       PEM may also affect NFκB activation by influencing cell redox status, possibly by 
decreased GSH concentration in the brain. Cysteine is the limiting amino acid for GSH 
synthesis (2). In PEM, decreased dietary cysteine leads to limited GSH synthesis (146). 
Decreased GSH has been demonstrated in the liver of protein-energy malnourished 
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gerbils (17) and in liver and lung of protein-energy deficient rats (158) and protein-
deficient mice (157). When substrate is limited, GSH may also be used to supply cysteine 
for critical proteins, resulting in a more vulnerable antioxidant defense system (224). The 
response of brain is less clear.  Bobyn et al (159) have shown decreased GSH 
concentration in neocortex and thalamus of rats with acute, severe dietary sulfur amino 
acid deficiency. However, brain GSH appeared to be well regulated and unaffected by a 
low protein diet in mice and rats (211, 225, 226). Although it was hypothesized that PEM 
would exacerbate a global ischemia-induced depletion of GSH due to decreased substrate 
for synthesis in the face of increased demand, brain GSH was not decreased by PEM at 
12 hr following global ischemia in previous studies in our laboratory (17). However, this 
will need to be re-evaluated in a more consistent model of global ischemia since GSH 
was not depleted by global ischemia in animals fed control diet, suggesting that oxidative 
stress was mild.  This is in contrast to most reports in global ischemia models in which 
brain GSH is markedly depleted (62, 184, 227, 228) and is likely related to varying 
degrees of ischemic severity in our failing global ischemia model.  
It is also possible that PEM increases NFκB activation through an increase in 
oxidative stress that is independent of a change in GSH concentration.  
This is supported by the study of Bobyn et al (17) which reported PEM- and ischemia-
induced decreases in hippocampal protein thiol levels and a trend (p=0.07) for GSH 
reductase activity in hippocampus to decrease with ischemia only when the animals were 
also protein-energy malnourished. These serve as markers of oxidative stress because of 
the susceptibility of thiols groups to oxidation (160).  
Other studies also support an increase in oxidative stress with protein deficiency.  
Increased protein carbonyls in hippocampus, as a marker of oxidative damage to proteins, 
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has been reported in protein malnourished rats, as has increased activity of the 
antioxidant enzyme, SOD (223). The latter can lead to the production of hydrogen 
peroxide, which can react with iron to generate hydroxyl radicals, which are believed to 
be the most toxic oxygen molecules in vivo (223). In patients with kwashiorkor, the 
plasma total antioxidant status has been reported to be reduced to less than 50% of that of 
healthy controls, whereas erythrocyte GSH concentration was decreased and plasma 
nitrite and nitrate were increased (229). This evidence suggests that PEM may affect cell 
redox status which could regulate NFκB activation and modify stroke outcome. 
       This study was also designed to rule out the possibility that PEM influences the 
outcome from global ischemia by altering serum glucose or GCs. These physiological 
variables are known to affect ischemic brain injury. Hyperglycemia has been reported in 
several brain ischemia models and is correlated with poor prognosis in ischemic stroke 
because elevated glucose levels lead to elevated intra-ischemic lactic acid levels and 
lactic acidosis, thus exacerbating brain damage (164). PEM has been shown in several 
studies to decrease serum glucose (21, 23), while insulin has been reported decreased to 
promote glucose homeostasis (24). However, in the model of malnutrition used in this 
study, serum glucose was not affected by PEM or ischemia, at least at 6 hr post-ischemia. 
Although only one timepoint has been measured so far, there is no evidence at present 
that PEM alters ischemic brain injury by influencing glucose homeostasis.  This question 
could be addressed better in the rat models of global ischemia in which the animal’s 
larger blood volume would allow blood sampling at several timepoints surrounding 
ischemia.  
       High GCs have been associated with cognitive dysfunction and severity of 
hemiparesis after stroke, and may predict poor stroke outcome (172-174). A high level of 
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GCs is often reported in response to acute deficits of protein and energy (24) although 
this varies with severity and age of onset of the deficiency. Blood cortisol in acutely 
protein-energy malnourished children (169) and serum corticosterone concentration in 
acutely protein-energy malnourished young adult rodents (171) have been reported to 
range from 1.3 to 6-fold that found in matched healthy subjects. As well as influencing 
ischemic brain injury, GC levels were of interest because of their ability to decrease 
NFκB activation (155). In the current study, we found no effect of PEM on serum cortisol 
concentration.  However, the serum cortisol data may be flawed as the levels were 
variable and unphysiologically high.  This is likely due to acute pre-anesthesia stress.  As 
stress-induced inflation of basal levels has been shown to mask an effect caused by PEM 
(230), these results should be confirmed in another study to confirm that PEM is not 
mediating its effects on ischemic outcome through increased circulating GCs.  Shipp and 
Woodward (230) have published a protocol for anesthesia induction and acclimatization 
of animals to transport and environment that minimizes this problem.  
In conclusion, the results of this study demonstrated that PEM increases hippocampal 
NFκB activation following global ischemia. Whether the increased NFκB activation 
causes an increase in its proinflammatory target genes is important to investigate in future 
studies, as the findings suggest that patients who are protein-energy compromised at the 
time of presentation for stroke will have an increased inflammatory response.  Whether 
PEM increases NFκB activation by increasing oxidative stress should also be studied in 
an alternate model of global ischemia in which neuronal damage is more consistent.  
These factors are essential for determining the death or survival of neurons following 
ischemia.  The data suggest that neither serum cortisol nor serum glucose influenced 
ischemic severity in the protein-energy malnourished gerbils, as neither parameter was 
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altered at 6 hr following global ischemia. Since PEM enhanced hippocampal NFκB 
activation in sham surgical controls and in the absence of surgery as well, the findings 
may also have other important implications for the inflammatory response of the many 
individuals affected globally by malnutrition. 
Future Directions: 
1. The results of this study have been significantly hampered by the high proportion 
of gerbils having a partial or complete circle of Willis.  This is known to cause 
high variability in hippocampal CA1 damage following bilateral carotid artery 
occlusion.  Therefore, an alternate global ischemia model, such as the rat 2-vessel 
or 4-vessel occlusion model, should be used for future studies.   
2.  It is important to further investigate which specific NFκB dimer is activated in 
hippocampus by PEM.  This can be done by using antibodies against p50 and p65 
in a supershift assay or DNA-binding ELISA. 
3. It is also important to investigate whether the increased NFκB activation observed 
with PEM causes an increase in its pro-inflammatory target genes such as TNF-α 
and IL-1β. This can be measured by RT-PCR, ELISA, and immunohistochemistry.  
4. Future studies should also investigate whether PEM decreases the cytosolic 
inhibitor, IκB, since phosphorylation and degradation of IκB allows NFκB 
translocation into the nucleus. IκB can be measured by ELISA.   
5. Whether PEM increases NFκB activation in other tissues, such as liver, kidney, 
heart and lung, needs to be determined as well so that the impact of PEM on the 
inflammatory response of the whole body can be revealed.  
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